Proactiveinvestors USA & Canada CytoDyn Inc. https://ca.proactiveinvestors.com Proactiveinvestors USA & Canada CytoDyn Inc. RSS feed en Tue, 22 Sep 2020 00:58:19 -0400 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) CytoDyn to meet with UK regulators to discuss Fast-Track approval for leronlimab, schedules sitdown with FDA https://ca.proactiveinvestors.com/companies/news/928152/cytodyn-to-meet-with-uk-regulators-to-discuss-fast-track-approval-for-leronlimab-schedules-sitdown-with-fda-928152.html Wed, 02 Sep 2020 20:45:00 -0400 https://ca.proactiveinvestors.com/companies/news/928152/cytodyn-to-meet-with-uk-regulators-to-discuss-fast-track-approval-for-leronlimab-schedules-sitdown-with-fda-928152.html CytoDyn forms Scientific Advisory Board, including leading HIV, NASH, Oncology, and Rheumatological clinical experts and researchers https://ca.proactiveinvestors.com/companies/news/927990/cytodyn-forms-scientific-advisory-board-including-leading-hiv-nash-oncology-and-rheumatological-clinical-experts-and-researchers-927990.html Tue, 01 Sep 2020 12:25:00 -0400 https://ca.proactiveinvestors.com/companies/news/927990/cytodyn-forms-scientific-advisory-board-including-leading-hiv-nash-oncology-and-rheumatological-clinical-experts-and-researchers-927990.html CytoDyn addresses WSJ & SeekingAlpha articles, calls on investors to pay attention to fundamentals https://ca.proactiveinvestors.com/companies/news/927630/cytodyn-addresses-wsj--seekingalpha-articles-calls-on-investors-to-pay-attention-to-fundamentals-927630.html Wed, 26 Aug 2020 19:17:00 -0400 https://ca.proactiveinvestors.com/companies/news/927630/cytodyn-addresses-wsj--seekingalpha-articles-calls-on-investors-to-pay-attention-to-fundamentals-927630.html CytoDyn reaches patient quota for Phase 3 leronlimab coronavirus trial; analysis expected in four weeks https://ca.proactiveinvestors.com/companies/news/927591/cytodyn-reaches-patient-quota-for-phase-3-leronlimab-coronavirus-trial-analysis-expected-in-four-weeks-927591.html Wed, 26 Aug 2020 12:35:00 -0400 https://ca.proactiveinvestors.com/companies/news/927591/cytodyn-reaches-patient-quota-for-phase-3-leronlimab-coronavirus-trial-analysis-expected-in-four-weeks-927591.html CytoDyn updates on Type A meeting with FDA, gets nod from UK proceed with Phase 3 coronavirus trial https://ca.proactiveinvestors.com/companies/news/927208/cytodyn-updates-on-type-a-meeting-with-fda-gets-nod-from-uk-proceed-with-phase-3-coronavirus-trial-927208.html Thu, 20 Aug 2020 17:29:00 -0400 https://ca.proactiveinvestors.com/companies/news/927208/cytodyn-updates-on-type-a-meeting-with-fda-gets-nod-from-uk-proceed-with-phase-3-coronavirus-trial-927208.html CytoDyn to submit leronlimab application questions to FDA; gets nod from UK regulators to proceed with coronavirus trial https://ca.proactiveinvestors.com/companies/news/927162/cytodyn-to-submit-leronlimab-application-questions-to-fda-gets-nod-from-uk-regulators-to-proceed-with-coronavirus-trial-927162.html Thu, 20 Aug 2020 12:45:00 -0400 https://ca.proactiveinvestors.com/companies/news/927162/cytodyn-to-submit-leronlimab-application-questions-to-fda-gets-nod-from-uk-regulators-to-proceed-with-coronavirus-trial-927162.html NA Proactive news snapshot: Cardiol Therapeutics, Revive Therapeutics, Ximen Mining, Canada Silver Cobalt Works, BioPorto, PUDO UPDATE … https://ca.proactiveinvestors.com/companies/news/927068/na-proactive-news-snapshot-cardiol-therapeutics-revive-therapeutics-ximen-mining-canada-silver-cobalt-works-bioporto-pudo-update--927068.html Wed, 19 Aug 2020 21:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/927068/na-proactive-news-snapshot-cardiol-therapeutics-revive-therapeutics-ximen-mining-canada-silver-cobalt-works-bioporto-pudo-update--927068.html CytoDyn requests fast track approval for leronlimab from UK regulators to treat coronavirus patients https://ca.proactiveinvestors.com/companies/news/927055/cytodyn-requests-fast-track-approval-for-leronlimab-from-uk-regulators-to-treat-coronavirus-patients-927055.html Wed, 19 Aug 2020 13:15:00 -0400 https://ca.proactiveinvestors.com/companies/news/927055/cytodyn-requests-fast-track-approval-for-leronlimab-from-uk-regulators-to-treat-coronavirus-patients-927055.html CytoDyn submits Phase 2 mild-to-moderate coronavirus patient data to the FDA https://ca.proactiveinvestors.com/companies/news/926862/cytodyn-submits-phase-2-mild-to-moderate-coronavirus-patient-data-to-the-fda-926862.html Mon, 17 Aug 2020 19:23:00 -0400 https://ca.proactiveinvestors.com/companies/news/926862/cytodyn-submits-phase-2-mild-to-moderate-coronavirus-patient-data-to-the-fda-926862.html CytoDyn sends leronlimab coronavirus trial results to FDA, offers update on HIV treatment progress https://ca.proactiveinvestors.com/companies/news/926823/cytodyn-sends-leronlimab-coronavirus-trial-results-to-fda-offers-update-on-hiv-treatment-progress-926823.html Mon, 17 Aug 2020 12:25:00 -0400 https://ca.proactiveinvestors.com/companies/news/926823/cytodyn-sends-leronlimab-coronavirus-trial-results-to-fda-offers-update-on-hiv-treatment-progress-926823.html CytoDyn reveals latest mild-to-moderate coronavirus patient data in Phase 2 trial https://ca.proactiveinvestors.com/companies/news/926529/cytodyn-reveals-latest-mild-to-moderate-coronavirus-patient-data-in-phase-2-trial-926529.html Wed, 12 Aug 2020 16:38:00 -0400 https://ca.proactiveinvestors.com/companies/news/926529/cytodyn-reveals-latest-mild-to-moderate-coronavirus-patient-data-in-phase-2-trial-926529.html CytoDyn's leronlimab delivers health improvements for coronavirus patients in Phase 2 trial https://ca.proactiveinvestors.com/companies/news/926410/cytodyn-s-leronlimab-delivers-health-improvements-for-coronavirus-patients-in-phase-2-trial-926410.html Tue, 11 Aug 2020 14:45:00 -0400 https://ca.proactiveinvestors.com/companies/news/926410/cytodyn-s-leronlimab-delivers-health-improvements-for-coronavirus-patients-in-phase-2-trial-926410.html CytoDyn to submit request for pre-submission meetings in U.K. for Leronlimab https://ca.proactiveinvestors.com/companies/news/926171/cytodyn-to-submit-request-for-pre-submission-meetings-in-uk-for-leronlimab-926171.html Fri, 07 Aug 2020 17:47:00 -0400 https://ca.proactiveinvestors.com/companies/news/926171/cytodyn-to-submit-request-for-pre-submission-meetings-in-uk-for-leronlimab-926171.html CytoDyn seeks UK approval for its flagship drug leronlimab for HIV and coronavirus https://ca.proactiveinvestors.com/companies/news/926135/cytodyn-seeks-uk-approval-for-its-flagship-drug-leronlimab-for-hiv-and-coronavirus-926135.html Fri, 07 Aug 2020 11:55:00 -0400 https://ca.proactiveinvestors.com/companies/news/926135/cytodyn-seeks-uk-approval-for-its-flagship-drug-leronlimab-for-hiv-and-coronavirus-926135.html CytoDyn’s Leronlimab receives positive DSMC recommendation in ongoing Phase 3 study https://ca.proactiveinvestors.com/companies/news/925951/cytodyns-leronlimab-receives-positive-dsmc-recommendation-in-ongoing-phase-3-study-925951.html Wed, 05 Aug 2020 19:41:00 -0400 https://ca.proactiveinvestors.com/companies/news/925951/cytodyns-leronlimab-receives-positive-dsmc-recommendation-in-ongoing-phase-3-study-925951.html CytoDyn says that independent safety review of Phase 3 leronlimab trials found no concerns https://ca.proactiveinvestors.com/companies/news/925840/cytodyn-says-that-independent-safety-review-of-phase-3-leronlimab-trials-found-no-concerns-925840.html Tue, 04 Aug 2020 20:44:00 -0400 https://ca.proactiveinvestors.com/companies/news/925840/cytodyn-says-that-independent-safety-review-of-phase-3-leronlimab-trials-found-no-concerns-925840.html CytoDyn addresses negative claims made by healthcare publication STAT on its coronavirus study https://ca.proactiveinvestors.com/companies/news/925623/cytodyn-addresses-negative-claims-made-by-healthcare-publication-stat-on-its-coronavirus-study-925623.html Fri, 31 Jul 2020 15:01:00 -0400 https://ca.proactiveinvestors.com/companies/news/925623/cytodyn-addresses-negative-claims-made-by-healthcare-publication-stat-on-its-coronavirus-study-925623.html CytoDyn Inc lands $28.5M convertible note financing to fund leronlimab advancement https://ca.proactiveinvestors.com/companies/news/925476/cytodyn-inc-lands-285m-convertible-note-financing-to-fund-leronlimab-advancement-925476.html Thu, 30 Jul 2020 12:40:00 -0400 https://ca.proactiveinvestors.com/companies/news/925476/cytodyn-inc-lands-285m-convertible-note-financing-to-fund-leronlimab-advancement-925476.html NA Proactive news snapshot: Atlas Engineered Products, Weekend Unlimited, Gatling Exploration, True Leaf Brands UPDATE ... https://ca.proactiveinvestors.com/companies/news/924737/na-proactive-news-snapshot-atlas-engineered-products-weekend-unlimited-gatling-exploration-true-leaf-brands-update--924737.html Tue, 21 Jul 2020 21:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/924737/na-proactive-news-snapshot-atlas-engineered-products-weekend-unlimited-gatling-exploration-true-leaf-brands-update--924737.html CytoDyn showcases its patient safety data from its Phase 2 coronavirus trial https://ca.proactiveinvestors.com/companies/news/924762/cytodyn-showcases-its-patient-safety-data-from-its-phase-2-coronavirus-trial-924762.html Tue, 21 Jul 2020 19:35:00 -0400 https://ca.proactiveinvestors.com/companies/news/924762/cytodyn-showcases-its-patient-safety-data-from-its-phase-2-coronavirus-trial-924762.html CytoDyn claims promising safety data from Phase 2 coronavirus trial of its drug leronlimab https://ca.proactiveinvestors.com/companies/news/924727/cytodyn-claims-promising-safety-data-from-phase-2-coronavirus-trial-of-its-drug-leronlimab-924727.html Tue, 21 Jul 2020 13:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/924727/cytodyn-claims-promising-safety-data-from-phase-2-coronavirus-trial-of-its-drug-leronlimab-924727.html CytoDyn files to uplist to the Nasdaq, updates on coronavirus trials https://ca.proactiveinvestors.com/companies/news/924514/cytodyn-files-to-uplist-to-the-nasdaq-updates-on-coronavirus-trials-924514.html Fri, 17 Jul 2020 16:01:00 -0400 https://ca.proactiveinvestors.com/companies/news/924514/cytodyn-files-to-uplist-to-the-nasdaq-updates-on-coronavirus-trials-924514.html CytoDyn files to uplist to tech-heavy Nasdaq stock exchange https://ca.proactiveinvestors.com/companies/news/924380/cytodyn-files-to-uplist-to-tech-heavy-nasdaq-stock-exchange-924380.html Thu, 16 Jul 2020 13:10:00 -0400 https://ca.proactiveinvestors.com/companies/news/924380/cytodyn-files-to-uplist-to-tech-heavy-nasdaq-stock-exchange-924380.html NA Proactive news snapshot: Ipsidy, Avalon GloboCare, BioSig Technologies, Co-Diagnostics, Black Iron, Thunderbird Entertainment UPDATE … https://ca.proactiveinvestors.com/companies/news/924053/na-proactive-news-snapshotipsidy-avalon-globocare-biosig-technologies-co-diagnostics-black-iron-thunderbird-entertainment-update--924053.html Mon, 13 Jul 2020 21:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/924053/na-proactive-news-snapshotipsidy-avalon-globocare-biosig-technologies-co-diagnostics-black-iron-thunderbird-entertainment-update--924053.html CytoDyn says FDA seeks more information to complete a review for leronlimab as a combination therapy for HIV patients https://ca.proactiveinvestors.com/companies/news/924021/cytodyn-says-fda-seeks-more-information-to-complete-a-review-for-leronlimab-as-a-combination-therapy-for-hiv-patients-924021.html Mon, 13 Jul 2020 11:55:00 -0400 https://ca.proactiveinvestors.com/companies/news/924021/cytodyn-says-fda-seeks-more-information-to-complete-a-review-for-leronlimab-as-a-combination-therapy-for-hiv-patients-924021.html CytoDyn says leronlimab prevents transmission of simian HIV in pre-clinical study on macaques https://ca.proactiveinvestors.com/companies/news/923717/cytodyn-says-leronlimab-prevents-transmission-of-simian-hiv-in-pre-clinical-study-on-macaques-923717.html Wed, 08 Jul 2020 12:45:00 -0400 https://ca.proactiveinvestors.com/companies/news/923717/cytodyn-says-leronlimab-prevents-transmission-of-simian-hiv-in-pre-clinical-study-on-macaques-923717.html CytoDyn executes agreement with American Regent for US distribution of Leronlimab as a coronavirus treatment https://ca.proactiveinvestors.com/companies/news/923488/cytodyn-executes-agreement-with-american-regent-for-us-distribution-of-leronlimab-as-a-coronavirus-treatment-923488.html Mon, 06 Jul 2020 11:50:00 -0400 https://ca.proactiveinvestors.com/companies/news/923488/cytodyn-executes-agreement-with-american-regent-for-us-distribution-of-leronlimab-as-a-coronavirus-treatment-923488.html NA Proactive news snapshot: Arizona Silver Exploration, Internet of Things, BioLargo, NetCents Technology, Bioasis Technologies, InnoCan Pharma UPDATE … https://ca.proactiveinvestors.com/companies/news/923324/na-proactive-news-snapshot-arizona-silver-exploration-internet-of-things-biolargo-netcents-technology-bioasis-technologies-innocan-pharma-update--923324.html Thu, 02 Jul 2020 21:02:00 -0400 https://ca.proactiveinvestors.com/companies/news/923324/na-proactive-news-snapshot-arizona-silver-exploration-internet-of-things-biolargo-netcents-technology-bioasis-technologies-innocan-pharma-update--923324.html CytoDyn releases video highlighting the science of how leronlimab works in immuno-oncology https://ca.proactiveinvestors.com/companies/news/923309/cytodyn-releases-video-highlighting-the-science-of-how-leronlimab-works-in-immuno-oncology-923309.html Thu, 02 Jul 2020 11:55:00 -0400 https://ca.proactiveinvestors.com/companies/news/923309/cytodyn-releases-video-highlighting-the-science-of-how-leronlimab-works-in-immuno-oncology-923309.html CytoDyn CEO calls Citron Research report 'false', updates on coronavirus clinical trials https://ca.proactiveinvestors.com/companies/news/923234/cytodyn-ceo-calls-citron-research-report--false--updates-on-coronavirus-clinical-trials-923234.html Wed, 01 Jul 2020 15:23:00 -0400 https://ca.proactiveinvestors.com/companies/news/923234/cytodyn-ceo-calls-citron-research-report--false--updates-on-coronavirus-clinical-trials-923234.html NA Proactive news snapshot: OTC Markets Group, NetCents Technology, EuroLife Brands, Pacton Gold, Tectonic Metals, Group Eleven Resources UPDATE ... https://ca.proactiveinvestors.com/companies/news/922995/na-proactive-news-snapshot-otc-markets-group-netcents-technology-eurolife-brands-pacton-gold-tectonic-metals-group-eleven-resources-update--922995.html Mon, 29 Jun 2020 21:02:00 -0400 https://ca.proactiveinvestors.com/companies/news/922995/na-proactive-news-snapshot-otc-markets-group-netcents-technology-eurolife-brands-pacton-gold-tectonic-metals-group-eleven-resources-update--922995.html CytoDyn partners with Mexican health authorities to conduct trial of leronlimab for critically ill coronavirus patients https://ca.proactiveinvestors.com/companies/news/922982/cytodyn-partners-with-mexican-health-authorities-to-conduct-trial-of-leronlimab-for-critically-ill-coronavirus-patients-922982.html Mon, 29 Jun 2020 13:20:00 -0400 https://ca.proactiveinvestors.com/companies/news/922982/cytodyn-partners-with-mexican-health-authorities-to-conduct-trial-of-leronlimab-for-critically-ill-coronavirus-patients-922982.html CytoDyn expects to exceed 75-patient enrollment in its coronavirus-focused Phase 2 clinical trial https://ca.proactiveinvestors.com/companies/news/921936/cytodyn-expects-to-exceed-75-patient-enrollment-in-its-coronavirus-focused-phase-2-clinical-trial-921936.html Mon, 15 Jun 2020 16:25:00 -0400 https://ca.proactiveinvestors.com/companies/news/921936/cytodyn-expects-to-exceed-75-patient-enrollment-in-its-coronavirus-focused-phase-2-clinical-trial-921936.html CytoDyn kicks off Phase 2 trial of leronlimab as treatment for NASH https://ca.proactiveinvestors.com/companies/news/921810/cytodyn-kicks-off-phase-2-trial-of-leronlimab-as-treatment-for-nash-921810.html Fri, 12 Jun 2020 13:20:00 -0400 https://ca.proactiveinvestors.com/companies/news/921810/cytodyn-kicks-off-phase-2-trial-of-leronlimab-as-treatment-for-nash-921810.html CytoDyn meets 75 patient enrollment for Phase 2 trial of leronlimab for patients with mild-to-moderate symptoms of COVID-19 https://ca.proactiveinvestors.com/companies/news/921739/cytodyn-meets-75-patient-enrollment-for-phase-2-trial-of-leronlimab-for-patients-with-mild-to-moderate-symptoms-of-covid-19-921739.html Thu, 11 Jun 2020 20:29:00 -0400 https://ca.proactiveinvestors.com/companies/news/921739/cytodyn-meets-75-patient-enrollment-for-phase-2-trial-of-leronlimab-for-patients-with-mild-to-moderate-symptoms-of-covid-19-921739.html CytoDyn expects to hear a completion date from regulators next month for its leronlimab license application https://ca.proactiveinvestors.com/companies/news/921359/cytodyn-expects-to-hear-a-completion-date-from-regulators-next-month-for-its-leronlimab-license-application-921359.html Mon, 08 Jun 2020 13:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/921359/cytodyn-expects-to-hear-a-completion-date-from-regulators-next-month-for-its-leronlimab-license-application-921359.html CytoDyn continues to works on licensing deals as FDA continues its review on patient data https://ca.proactiveinvestors.com/companies/news/921298/cytodyn-continues-to-works-on-licensing-deals-as-fda-continues-its-review-on-patient-data-921298.html Fri, 05 Jun 2020 15:56:00 -0400 https://ca.proactiveinvestors.com/companies/news/921298/cytodyn-continues-to-works-on-licensing-deals-as-fda-continues-its-review-on-patient-data-921298.html CytoDyn asks regulator to review its application to license leronlimab for HIV treatment under priority designation https://ca.proactiveinvestors.com/companies/news/920835/cytodyn-asks-regulator-to-review-its-application-to-license-leronlimab-for-hiv-treatment-under-priority-designation-920835.html Mon, 01 Jun 2020 12:46:00 -0400 https://ca.proactiveinvestors.com/companies/news/920835/cytodyn-asks-regulator-to-review-its-application-to-license-leronlimab-for-hiv-treatment-under-priority-designation-920835.html CytoDyn to work with Mexican National Institutes of Health to treat coronavirus patients https://ca.proactiveinvestors.com/companies/news/920086/cytodyn-to-work-with-mexican-national-institutes-of-health-to-treat-coronavirus-patients-920086.html Wed, 20 May 2020 16:52:00 -0400 https://ca.proactiveinvestors.com/companies/news/920086/cytodyn-to-work-with-mexican-national-institutes-of-health-to-treat-coronavirus-patients-920086.html CytoDyn co-ordinates with Mexican Institutes of Health on leronlimab trial for severe coronavirus patients https://ca.proactiveinvestors.com/companies/news/919946/cytodyn-co-ordinates-with-mexican-institutes-of-health-on-leronlimab-trial-for-severe-coronavirus-patients-919946.html Tue, 19 May 2020 12:40:00 -0400 https://ca.proactiveinvestors.com/companies/news/919946/cytodyn-co-ordinates-with-mexican-institutes-of-health-on-leronlimab-trial-for-severe-coronavirus-patients-919946.html NA Proactive news snapshot: Arcadia Biosciences, Co-Diagnostics, OTC Markets Group, Champignon Brands UPDATE ... https://ca.proactiveinvestors.com/companies/news/919851/na-proactive-news-snapshot-arcadia-biosciences-co-diagnostics-otc-markets-group-champignon-brands-update--919851.html Mon, 18 May 2020 21:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/919851/na-proactive-news-snapshot-arcadia-biosciences-co-diagnostics-otc-markets-group-champignon-brands-update--919851.html CytoDyn to submit trial designs of remdesivir vs leronlimab and in combination to battle coronavirus https://ca.proactiveinvestors.com/companies/news/919864/cytodyn-to-submit-trial-designs-of-remdesivir-vs-leronlimab-and-in-combination-to-battle-coronavirus-919864.html Mon, 18 May 2020 17:03:00 -0400 https://ca.proactiveinvestors.com/companies/news/919864/cytodyn-to-submit-trial-designs-of-remdesivir-vs-leronlimab-and-in-combination-to-battle-coronavirus-919864.html CytoDyn unveils further clinical trial plans in bid to fight coronavirus pandemic https://ca.proactiveinvestors.com/companies/news/919836/cytodyn-unveils-further-clinical-trial-plans-in-bid-to-fight-coronavirus-pandemic-919836.html Mon, 18 May 2020 15:03:00 -0400 https://ca.proactiveinvestors.com/companies/news/919836/cytodyn-unveils-further-clinical-trial-plans-in-bid-to-fight-coronavirus-pandemic-919836.html CytoDyn partner to offer free testing for coronavirus-linked Childhood Inflammatory Disease https://ca.proactiveinvestors.com/companies/news/919745/cytodyn-partner-to-offer-free-testing-for-coronavirus-linked-childhood-inflammatory-disease-919745.html Fri, 15 May 2020 15:16:00 -0400 https://ca.proactiveinvestors.com/companies/news/919745/cytodyn-partner-to-offer-free-testing-for-coronavirus-linked-childhood-inflammatory-disease-919745.html CytoDyn partner offers free lab testing for coronavirus-linked Childhood Inflammatory Diseases https://ca.proactiveinvestors.com/companies/news/919720/cytodyn-partner-offers-free-lab-testing-for-coronavirus-linked-childhood-inflammatory-diseases-919720.html Fri, 15 May 2020 13:05:00 -0400 https://ca.proactiveinvestors.com/companies/news/919720/cytodyn-partner-offers-free-lab-testing-for-coronavirus-linked-childhood-inflammatory-diseases-919720.html CytoDyn wraps up Biologics License Application for leronlimab as combination HIV therapy https://ca.proactiveinvestors.com/companies/news/919493/cytodyn-wraps-up-biologics-license-application-for-leronlimab-as-combination-hiv-therapy-919493.html Wed, 13 May 2020 13:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/919493/cytodyn-wraps-up-biologics-license-application-for-leronlimab-as-combination-hiv-therapy-919493.html CytoDyn to submit additional leronlimab documents to FDA for Biologics License Application https://ca.proactiveinvestors.com/companies/news/919269/cytodyn-to-submit-additional-leronlimab-documents-to-fda-for-biologics-license-application-919269.html Mon, 11 May 2020 12:45:00 -0400 https://ca.proactiveinvestors.com/companies/news/919269/cytodyn-to-submit-additional-leronlimab-documents-to-fda-for-biologics-license-application-919269.html NA Proactive news snapshot: Codebase Ventures, NetCents, Aurania Resources, Medexus Pharmaceuticals UPDATE ... https://ca.proactiveinvestors.com/companies/news/919167/na-proactive-news-snapshot-codebase-ventures-netcents-aurania-resources-medexus-pharmaceuticals-update--919167.html Fri, 08 May 2020 20:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/919167/na-proactive-news-snapshot-codebase-ventures-netcents-aurania-resources-medexus-pharmaceuticals-update--919167.html CytoDyn says Novant Health initiates Phase 2b/3 trial with leronlimab for critically ill coronavirus patients https://ca.proactiveinvestors.com/companies/news/919159/cytodyn-says-novant-health-initiates-phase-2b3-trial-with-leronlimab-for-critically-ill-coronavirus-patients-919159.html Fri, 08 May 2020 11:55:00 -0400 https://ca.proactiveinvestors.com/companies/news/919159/cytodyn-says-novant-health-initiates-phase-2b3-trial-with-leronlimab-for-critically-ill-coronavirus-patients-919159.html CytoDyn shares manuscript of potential coronavirus treatment to show validity of study's findings https://ca.proactiveinvestors.com/companies/news/919012/cytodyn-shares-manuscript-of-potential-coronavirus-treatment-to-show-validity-of-study-s-findings-919012.html Wed, 06 May 2020 17:05:00 -0400 https://ca.proactiveinvestors.com/companies/news/919012/cytodyn-shares-manuscript-of-potential-coronavirus-treatment-to-show-validity-of-study-s-findings-919012.html CytoDyn posts manuscript on how its drug leronlimab restores immune balance in critical coronavirus patients https://ca.proactiveinvestors.com/companies/news/918976/cytodyn-posts-manuscript-on-how-its-drug-leronlimab-restores-immune-balance-in-critical-coronavirus-patients-918976.html Wed, 06 May 2020 12:15:00 -0400 https://ca.proactiveinvestors.com/companies/news/918976/cytodyn-posts-manuscript-on-how-its-drug-leronlimab-restores-immune-balance-in-critical-coronavirus-patients-918976.html CytoDyn expects to fully enroll its trials to treat coronavirus patients by end of May https://ca.proactiveinvestors.com/companies/news/918774/cytodyn-expects-to-fully-enroll-its-trials-to-treat-coronavirus-patients-by-end-of-may-918774.html Mon, 04 May 2020 16:22:00 -0400 https://ca.proactiveinvestors.com/companies/news/918774/cytodyn-expects-to-fully-enroll-its-trials-to-treat-coronavirus-patients-by-end-of-may-918774.html CytoDyn to wrap up leronlimab coronavirus trial enrolment this month; asking FDA to expand access to patients who don't qualify https://ca.proactiveinvestors.com/companies/news/918750/cytodyn-to-wrap-up-leronlimab-coronavirus-trial-enrolment-this-month-asking-fda-to-expand-access-to-patients-who-don-t-qualify-918750.html Mon, 04 May 2020 13:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/918750/cytodyn-to-wrap-up-leronlimab-coronavirus-trial-enrolment-this-month-asking-fda-to-expand-access-to-patients-who-don-t-qualify-918750.html NA Proactive news snapshot: Helix Technologies, Phunware, Surge Holdings, Marrone Bio, Dyadic... UPDATE https://ca.proactiveinvestors.com/companies/news/918558/na-proactive-news-snapshot-helix-technologies-phunware-surge-holdings-marrone-bio-dyadic-update-918558.html Thu, 30 Apr 2020 21:08:00 -0400 https://ca.proactiveinvestors.com/companies/news/918558/na-proactive-news-snapshot-helix-technologies-phunware-surge-holdings-marrone-bio-dyadic-update-918558.html CytoDyn continues to report strong results from COVID-19 patients using Leronlimab https://ca.proactiveinvestors.com/companies/news/918569/cytodyn-continues-to-report-strong-results-from-covid-19-patients-using-leronlimab-918569.html Thu, 30 Apr 2020 16:49:00 -0400 https://ca.proactiveinvestors.com/companies/news/918569/cytodyn-continues-to-report-strong-results-from-covid-19-patients-using-leronlimab-918569.html CytoDyn sees coronavirus patients in emergency IND program treated with leronlimab make ‘remarkable recoveries’ https://ca.proactiveinvestors.com/companies/news/918535/cytodyn-sees-coronavirus-patients-in-emergency-ind-program-treated-with-leronlimab-make-remarkable-recoveries-918535.html Thu, 30 Apr 2020 12:20:00 -0400 https://ca.proactiveinvestors.com/companies/news/918535/cytodyn-sees-coronavirus-patients-in-emergency-ind-program-treated-with-leronlimab-make-remarkable-recoveries-918535.html CytoDyn shares jump as it submits leronlimab license application to FDA; names Mulholland as interim finance chief https://ca.proactiveinvestors.com/companies/news/918203/cytodyn-shares-jump-as-it-submits-leronlimab-license-application-to-fda-names-mulholland-as-interim-finance-chief-918203.html Mon, 27 Apr 2020 14:35:00 -0400 https://ca.proactiveinvestors.com/companies/news/918203/cytodyn-shares-jump-as-it-submits-leronlimab-license-application-to-fda-names-mulholland-as-interim-finance-chief-918203.html CytoDyn names biotech entrepreneur Dr Samir Patel to its board https://ca.proactiveinvestors.com/companies/news/917642/cytodyn-names-biotech-entrepreneur-dr-samir-patel-to-its-board-917642.html Mon, 20 Apr 2020 13:20:00 -0400 https://ca.proactiveinvestors.com/companies/news/917642/cytodyn-names-biotech-entrepreneur-dr-samir-patel-to-its-board-917642.html CytoDyn treats first patient in its Phase 2b/3 coronavirus trial along with its its first patient in its Phase 2 basket trial https://ca.proactiveinvestors.com/companies/news/917336/cytodyn-treats-first-patient-in-its-phase-2b3-coronavirus-trial-along-with-its-its-first-patient-in-its-phase-2-basket-trial-917336.html Wed, 15 Apr 2020 18:08:00 -0400 https://ca.proactiveinvestors.com/companies/news/917336/cytodyn-treats-first-patient-in-its-phase-2b3-coronavirus-trial-along-with-its-its-first-patient-in-its-phase-2-basket-trial-917336.html CytoDyn Inc’s first patient treated with flagship drug leronlimab in Phase 2b/3 trial for coronavirus https://ca.proactiveinvestors.com/companies/news/917307/cytodyn-incs-first-patient-treated-with-flagship-drug-leronlimab-in-phase-2b3-trial-for-coronavirus-917307.html Wed, 15 Apr 2020 12:15:00 -0400 https://ca.proactiveinvestors.com/companies/news/917307/cytodyn-incs-first-patient-treated-with-flagship-drug-leronlimab-in-phase-2b3-trial-for-coronavirus-917307.html CytoDyn sees 'strong results' from leronlimab-treated coronavirus patients released from hospitals https://ca.proactiveinvestors.com/companies/news/917109/cytodyn-sees--strong-results--from-leronlimab-treated-coronavirus-patients-released-from-hospitals-917109.html Mon, 13 Apr 2020 18:24:00 -0400 https://ca.proactiveinvestors.com/companies/news/917109/cytodyn-sees--strong-results--from-leronlimab-treated-coronavirus-patients-released-from-hospitals-917109.html CytoDyn Inc says five coronavirus patients able to go off oxygen after taking leronlimab https://ca.proactiveinvestors.com/companies/news/917093/cytodyn-inc-says-five-coronavirus-patients-able-to-go-off-oxygen-after-taking-leronlimab-917093.html Mon, 13 Apr 2020 12:32:00 -0400 https://ca.proactiveinvestors.com/companies/news/917093/cytodyn-inc-says-five-coronavirus-patients-able-to-go-off-oxygen-after-taking-leronlimab-917093.html CytoDyn hopes to convince FDA & federal gov't to grant approvals with coronavirus patient data https://ca.proactiveinvestors.com/companies/news/917080/cytodyn-hopes-to-convince-fda--federal-gov-t-to-grant-approvals-with-coronavirus-patient-data-917080.html Thu, 09 Apr 2020 17:32:00 -0400 https://ca.proactiveinvestors.com/companies/news/917080/cytodyn-hopes-to-convince-fda--federal-gov-t-to-grant-approvals-with-coronavirus-patient-data-917080.html CytoDyn says severe coronavirus patients treated with leronlimab drug show significant improvement https://ca.proactiveinvestors.com/companies/news/917046/cytodyn-says-severe-coronavirus-patients-treated-with-leronlimab-drug-show-significant-improvement-917046.html Thu, 09 Apr 2020 12:50:00 -0400 https://ca.proactiveinvestors.com/companies/news/917046/cytodyn-says-severe-coronavirus-patients-treated-with-leronlimab-drug-show-significant-improvement-917046.html CytoDyn announces first site in the southeastern USA to enroll patients in Phase 2 coronavirus trial https://ca.proactiveinvestors.com/companies/news/916936/cytodyn-announces-first-site-in-the-southeastern-usa-to-enroll-patients-in-phase-2-coronavirus-trial-916936.html Wed, 08 Apr 2020 12:05:00 -0400 https://ca.proactiveinvestors.com/companies/news/916936/cytodyn-announces-first-site-in-the-southeastern-usa-to-enroll-patients-in-phase-2-coronavirus-trial-916936.html NA Proactive news snapshot: Phunware, Antibe, LeanLife, Ideanomics, Steppe Gold, Parallax Health Sciences UPDATE … https://ca.proactiveinvestors.com/companies/news/916830/na-proactive-news-snapshot-phunware-antibe-leanlife-ideanomics-steppe-gold-parallax-health-sciences-update--916830.html Tue, 07 Apr 2020 21:05:00 -0400 https://ca.proactiveinvestors.com/companies/news/916830/na-proactive-news-snapshot-phunware-antibe-leanlife-ideanomics-steppe-gold-parallax-health-sciences-update--916830.html CytoDyn Inc to begin enrolling severe and critically ill coronavirus patients in Phase 2b/3 trial https://ca.proactiveinvestors.com/companies/news/916854/cytodyn-inc-to-begin-enrolling-severe-and-critically-ill-coronavirus-patients-in-phase-2b3-trial-916854.html Tue, 07 Apr 2020 17:07:00 -0400 https://ca.proactiveinvestors.com/companies/news/916854/cytodyn-inc-to-begin-enrolling-severe-and-critically-ill-coronavirus-patients-in-phase-2b3-trial-916854.html CytoDyn collaborating with UK’s Department of Health to provide emergency access to leronlimab for critically ill coronavirus patients https://ca.proactiveinvestors.com/companies/news/916815/cytodyn-collaborating-with-uks-department-of-health-to-provide-emergency-access-to-leronlimab-for-critically-ill-coronavirus-patients-916815.html Tue, 07 Apr 2020 12:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/916815/cytodyn-collaborating-with-uks-department-of-health-to-provide-emergency-access-to-leronlimab-for-critically-ill-coronavirus-patients-916815.html CytoDyn treats two coronavirus patients in Phase 2 trial https://ca.proactiveinvestors.com/companies/news/916741/cytodyn-treats-two-coronavirus-patients-in-phase-2-trial-916741.html Mon, 06 Apr 2020 17:04:00 -0400 https://ca.proactiveinvestors.com/companies/news/916741/cytodyn-treats-two-coronavirus-patients-in-phase-2-trial-916741.html CytoDyn enrolls two patients in Phase 2 coronavirus trial of leronlimab; 15 severely ill patients treated separately so far https://ca.proactiveinvestors.com/companies/news/916711/cytodyn-enrolls-two-patients-in-phase-2-coronavirus-trial-of-leronlimab-15-severely-ill-patients-treated-separately-so-far-916711.html Mon, 06 Apr 2020 12:40:00 -0400 https://ca.proactiveinvestors.com/companies/news/916711/cytodyn-enrolls-two-patients-in-phase-2-coronavirus-trial-of-leronlimab-15-severely-ill-patients-treated-separately-so-far-916711.html CytoDyn requests initial meeting with FDA for Breakthrough Therapy status for leronlimab in treating cancer https://ca.proactiveinvestors.com/companies/news/916600/cytodyn-requests-initial-meeting-with-fda-for-breakthrough-therapy-status-for-leronlimab-in-treating-cancer-916600.html Fri, 03 Apr 2020 11:50:00 -0400 https://ca.proactiveinvestors.com/companies/news/916600/cytodyn-requests-initial-meeting-with-fda-for-breakthrough-therapy-status-for-leronlimab-in-treating-cancer-916600.html CytoDyn sees impressive results with Leronlimab on very ill COVID-19 patients https://ca.proactiveinvestors.com/companies/news/916527/cytodyn-sees-impressive-results-with-leronlimab-on-very-ill-covid-19-patients-916527.html Thu, 02 Apr 2020 17:24:00 -0400 https://ca.proactiveinvestors.com/companies/news/916527/cytodyn-sees-impressive-results-with-leronlimab-on-very-ill-covid-19-patients-916527.html CytoDyn says coronavirus patients treated with leronlimab show initial improvements after three days https://ca.proactiveinvestors.com/companies/news/916491/cytodyn-says-coronavirus-patients-treated-with-leronlimab-show-initial-improvements-after-three-days-916491.html Thu, 02 Apr 2020 12:40:00 -0400 https://ca.proactiveinvestors.com/companies/news/916491/cytodyn-says-coronavirus-patients-treated-with-leronlimab-show-initial-improvements-after-three-days-916491.html CytoDyn files second clinical trial protocol to treat severely ill coronavirus patients with lernlimab https://ca.proactiveinvestors.com/companies/news/916364/cytodyn-files-second-clinical-trial-protocol-to-treat-severely-ill-coronavirus-patients-with-lernlimab-916364.html Wed, 01 Apr 2020 13:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/916364/cytodyn-files-second-clinical-trial-protocol-to-treat-severely-ill-coronavirus-patients-with-lernlimab-916364.html NA Proactive news snapshot: Newgioco, Co-Diagnostics, Gevo, Mineworx Technologies UPDATE … https://ca.proactiveinvestors.com/companies/news/916254/na-proactive-news-snapshot-newgioco-co-diagnostics-gevo-mineworx-technologies-update--916254.html Tue, 31 Mar 2020 21:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/916254/na-proactive-news-snapshot-newgioco-co-diagnostics-gevo-mineworx-technologies-update--916254.html CytoDyn Get US FDA approval to move to FastTrack to Phase 2 trial for COVID-19 https://ca.proactiveinvestors.com/companies/news/916277/cytodyn-get-us-fda-approval-to-move-to-fasttrack-to-phase-2-trial-for-covid-19-916277.html Tue, 31 Mar 2020 19:15:00 -0400 https://ca.proactiveinvestors.com/companies/news/916277/cytodyn-get-us-fda-approval-to-move-to-fasttrack-to-phase-2-trial-for-covid-19-916277.html CytoDyn’s Phase 2 trial to treat mild-to-moderately ill coronavirus patients with leronlimab cleared by the FDA https://ca.proactiveinvestors.com/companies/news/916235/cytodyns-phase-2-trial-to-treat-mild-to-moderately-ill-coronavirus-patients-with-leronlimab-cleared-by-the-fda-916235.html Tue, 31 Mar 2020 11:45:00 -0400 https://ca.proactiveinvestors.com/companies/news/916235/cytodyns-phase-2-trial-to-treat-mild-to-moderately-ill-coronavirus-patients-with-leronlimab-cleared-by-the-fda-916235.html CytoDyn sees three more coronavirus patients in New York treated with its drug leronlimab https://ca.proactiveinvestors.com/companies/news/916109/cytodyn-sees-three-more-coronavirus-patients-in-new-york-treated-with-its-drug-leronlimab-916109.html Mon, 30 Mar 2020 11:50:00 -0400 https://ca.proactiveinvestors.com/companies/news/916109/cytodyn-sees-three-more-coronavirus-patients-in-new-york-treated-with-its-drug-leronlimab-916109.html NA Proactive news snapshot: Ideanomics, GR Silver Mining, Naturally Splendid Enterprises, EnWave UPDATE … https://ca.proactiveinvestors.com/companies/news/915998/na-proactive-news-snapshot-ideanomics-gr-silver-mining-naturally-splendid-enterprises-enwave-update--915998.html Fri, 27 Mar 2020 20:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/915998/na-proactive-news-snapshot-ideanomics-gr-silver-mining-naturally-splendid-enterprises-enwave-update--915998.html CytoDyn's therapy used to treat New York coronavirus patients shows 'immunological benefits' https://ca.proactiveinvestors.com/companies/news/916025/cytodyn-s-therapy-used-to-treat-new-york-coronavirus-patients-shows--immunological-benefits--916025.html Fri, 27 Mar 2020 19:23:00 -0400 https://ca.proactiveinvestors.com/companies/news/916025/cytodyn-s-therapy-used-to-treat-new-york-coronavirus-patients-shows--immunological-benefits--916025.html CytoDyn sees positive test results from seven coronavirus patients in New York treated with its drug Leronlimab https://ca.proactiveinvestors.com/companies/news/915986/cytodyn-sees-positive-test-results-from-seven-coronavirus-patients-in-new-york-treated-with-its-drug-leronlimab-915986.html Fri, 27 Mar 2020 12:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/915986/cytodyn-sees-positive-test-results-from-seven-coronavirus-patients-in-new-york-treated-with-its-drug-leronlimab-915986.html CytoDyn sees two more coronavirus patients in New York treated with its drug leronlimab https://ca.proactiveinvestors.com/companies/news/915528/cytodyn-sees-two-more-coronavirus-patients-in-new-york-treated-with-its-drug-leronlimab-915528.html Mon, 23 Mar 2020 12:35:00 -0400 https://ca.proactiveinvestors.com/companies/news/915528/cytodyn-sees-two-more-coronavirus-patients-in-new-york-treated-with-its-drug-leronlimab-915528.html CytoDyn says two coronavirus patients in New York treated with its leronlimab drug https://ca.proactiveinvestors.com/companies/news/915328/cytodyn-says-two-coronavirus-patients-in-new-york-treated-with-its-leronlimab-drug-915328.html Thu, 19 Mar 2020 12:45:00 -0400 https://ca.proactiveinvestors.com/companies/news/915328/cytodyn-says-two-coronavirus-patients-in-new-york-treated-with-its-leronlimab-drug-915328.html NA Proactive news snapshot: Ideanomics, Lexaria Bioscience, Seelos Therapeutics, Helix BioPharma UPDATE … https://ca.proactiveinvestors.com/companies/news/915033/na-proactive-news-snapshot-ideanomics-lexaria-bioscience-seelos-therapeutics-helix-biopharma-update--915033.html Mon, 16 Mar 2020 21:10:00 -0400 https://ca.proactiveinvestors.com/companies/news/915033/na-proactive-news-snapshot-ideanomics-lexaria-bioscience-seelos-therapeutics-helix-biopharma-update--915033.html CytoDyn files modified protocol for Leronlimab trial battling respiratory complications as a result of contracting Coronavirus https://ca.proactiveinvestors.com/companies/news/915047/cytodyn-files-modified-protocol-for-leronlimab-trial-battling-respiratory-complications-as-a-result-of-contracting-coronavirus-915047.html Mon, 16 Mar 2020 16:07:00 -0400 https://ca.proactiveinvestors.com/companies/news/915047/cytodyn-files-modified-protocol-for-leronlimab-trial-battling-respiratory-complications-as-a-result-of-contracting-coronavirus-915047.html CytoDyn files modified IND and protocol for Phase 2 clinical trial of leronlimab as a treatment for coronavirus respiratory symptoms https://ca.proactiveinvestors.com/companies/news/915016/cytodyn-files-modified-ind-and-protocol-for-phase-2-clinical-trial-of-leronlimab-as-a-treatment-for-coronavirus-respiratory-symptoms-915016.html Mon, 16 Mar 2020 12:05:00 -0400 https://ca.proactiveinvestors.com/companies/news/915016/cytodyn-files-modified-ind-and-protocol-for-phase-2-clinical-trial-of-leronlimab-as-a-treatment-for-coronavirus-respiratory-symptoms-915016.html CytoDyn names Dr Jacob P. Lalezari as its interim chief medical officer https://ca.proactiveinvestors.com/companies/news/914923/cytodyn-names-dr-jacob-p-lalezari-as-its-interim-chief-medical-officer-914923.html Fri, 13 Mar 2020 15:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/914923/cytodyn-names-dr-jacob-p-lalezari-as-its-interim-chief-medical-officer-914923.html CytoDyn gets FDA nod for a preliminary Breakthrough Therapy designation meeting for leronlimab https://ca.proactiveinvestors.com/companies/news/914864/cytodyn-gets-fda-nod-for-a-preliminary-breakthrough-therapy-designation-meeting-for-leronlimab-914864.html Thu, 12 Mar 2020 14:07:00 -0400 https://ca.proactiveinvestors.com/companies/news/914864/cytodyn-gets-fda-nod-for-a-preliminary-breakthrough-therapy-designation-meeting-for-leronlimab-914864.html CytoDyn files investigational new drug application with FDA for coronavirus symptom treatment https://ca.proactiveinvestors.com/companies/news/914782/cytodyn-files-investigational-new-drug-application-with-fda-for-coronavirus-symptom-treatment-914782.html Wed, 11 Mar 2020 18:41:00 -0400 https://ca.proactiveinvestors.com/companies/news/914782/cytodyn-files-investigational-new-drug-application-with-fda-for-coronavirus-symptom-treatment-914782.html CytoDyn files with the FDA to study leronlimab as a treatment for coronavirus respiratory symptoms https://ca.proactiveinvestors.com/companies/news/914570/cytodyn-files-with-the-fda-to-study-leronlimab-as-a-treatment-for-coronavirus-respiratory-symptoms-914570.html Mon, 09 Mar 2020 13:21:00 -0400 https://ca.proactiveinvestors.com/companies/news/914570/cytodyn-files-with-the-fda-to-study-leronlimab-as-a-treatment-for-coronavirus-respiratory-symptoms-914570.html NA Proactive news snapshot: PyroGenesis Canada, Lexaria Bioscience, American Battery Metals, Exactus UPDATE … https://ca.proactiveinvestors.com/companies/news/914317/na-proactive-news-snapshot-pyrogenesis-canada-lexaria-bioscience-american-battery-metals-exactus-update--914317.html Wed, 04 Mar 2020 22:04:00 -0500 https://ca.proactiveinvestors.com/companies/news/914317/na-proactive-news-snapshot-pyrogenesis-canada-lexaria-bioscience-american-battery-metals-exactus-update--914317.html CytoDyn treats first patient with leronlimab in Phase 2 trial for GvHD under modified protocol https://ca.proactiveinvestors.com/companies/news/914309/cytodyn-treats-first-patient-with-leronlimab-in-phase-2-trial-for-gvhd-under-modified-protocol-914309.html Wed, 04 Mar 2020 13:33:00 -0500 https://ca.proactiveinvestors.com/companies/news/914309/cytodyn-treats-first-patient-with-leronlimab-in-phase-2-trial-for-gvhd-under-modified-protocol-914309.html NA Proactive news snapshot: GlobeX Data, Gold Resource, OTC Markets Group, Hill Street Beverage UPDATE ... https://ca.proactiveinvestors.com/companies/news/914065/na-proactive-news-snapshot-globex-data-gold-resource-otc-markets-group-hill-street-beverage-update--914065.html Mon, 02 Mar 2020 22:04:00 -0500 https://ca.proactiveinvestors.com/companies/news/914065/na-proactive-news-snapshot-globex-data-gold-resource-otc-markets-group-hill-street-beverage-update--914065.html CytoDyn's leronlimab 'working beautifully' in metastatic triple-negative breast cancer patients https://ca.proactiveinvestors.com/companies/news/914105/cytodyn-s-leronlimab--working-beautifully--in-metastatic-triple-negative-breast-cancer-patients-914105.html Mon, 02 Mar 2020 18:55:00 -0500 https://ca.proactiveinvestors.com/companies/news/914105/cytodyn-s-leronlimab--working-beautifully--in-metastatic-triple-negative-breast-cancer-patients-914105.html CytoDyn sees ‘remarkable outcomes’ in metastatic triple-negative breast cancer trial for leronlimab https://ca.proactiveinvestors.com/companies/news/914061/cytodyn-sees-remarkable-outcomes-in-metastatic-triple-negative-breast-cancer-trial-for-leronlimab-914061.html Mon, 02 Mar 2020 13:21:00 -0500 https://ca.proactiveinvestors.com/companies/news/914061/cytodyn-sees-remarkable-outcomes-in-metastatic-triple-negative-breast-cancer-trial-for-leronlimab-914061.html CytoDyn reveals plans for its Phase 2 basket trial to treat 22 different solid tumor cancers https://ca.proactiveinvestors.com/companies/news/913672/cytodyn-reveals-plans-for-its-phase-2-basket-trial-to-treat-22-different-solid-tumor-cancers-913672.html Tue, 25 Feb 2020 18:56:00 -0500 https://ca.proactiveinvestors.com/companies/news/913672/cytodyn-reveals-plans-for-its-phase-2-basket-trial-to-treat-22-different-solid-tumor-cancers-913672.html NA Proactive news snapshot: CytoDyn, Mandalay Resources, CleanSpark, Duos Technologies, Quantum Computing - UPDATE https://ca.proactiveinvestors.com/companies/news/913435/na-proactive-news-snapshot-cytodyn-mandalay-resources-cleanspark-duos-technologies-quantum-computing---update-913435.html Fri, 21 Feb 2020 21:00:00 -0500 https://ca.proactiveinvestors.com/companies/news/913435/na-proactive-news-snapshot-cytodyn-mandalay-resources-cleanspark-duos-technologies-quantum-computing---update-913435.html CytoDyn to begin Phase 2 trial of leronlimab targeting 22 different solid tumor cancers https://ca.proactiveinvestors.com/companies/news/913428/cytodyn-to-begin-phase-2-trial-of-leronlimab-targeting-22-different-solid-tumor-cancers-913428.html Fri, 21 Feb 2020 12:48:00 -0500 https://ca.proactiveinvestors.com/companies/news/913428/cytodyn-to-begin-phase-2-trial-of-leronlimab-targeting-22-different-solid-tumor-cancers-913428.html CytoDyn CEO Nader Pourhassan talks leronlimab's commercial potential on RedChip Money Report https://ca.proactiveinvestors.com/companies/news/913377/cytodyn-ceo-nader-pourhassan-talks-leronlimab-s-commercial-potential-on-redchip-money-report-913377.html Thu, 20 Feb 2020 20:42:00 -0500 https://ca.proactiveinvestors.com/companies/news/913377/cytodyn-ceo-nader-pourhassan-talks-leronlimab-s-commercial-potential-on-redchip-money-report-913377.html CytoDyn sees positive data for leronlimab in Phase 1b/2 mTNBC and expanded access studies for MBC https://ca.proactiveinvestors.com/companies/news/912982/cytodyn-sees-positive-data-for-leronlimab-in-phase-1b2-mtnbc-and-expanded-access-studies-for-mbc-912982.html Fri, 14 Feb 2020 13:50:00 -0500 https://ca.proactiveinvestors.com/companies/news/912982/cytodyn-sees-positive-data-for-leronlimab-in-phase-1b2-mtnbc-and-expanded-access-studies-for-mbc-912982.html CytoDyn forms partnership with Chinese medical services provider to fight deadly coronavirus https://ca.proactiveinvestors.com/companies/news/912806/cytodyn-forms-partnership-with-chinese-medical-services-provider-to-fight-deadly-coronavirus-912806.html Wed, 12 Feb 2020 17:33:00 -0500 https://ca.proactiveinvestors.com/companies/news/912806/cytodyn-forms-partnership-with-chinese-medical-services-provider-to-fight-deadly-coronavirus-912806.html CytoDyn links up with Chinese medical services firm to utilize leronlimab against the coronavirus https://ca.proactiveinvestors.com/companies/news/912787/cytodyn-links-up-with-chinese-medical-services-firm-to-utilize-leronlimab-against-the-coronavirus-912787.html Wed, 12 Feb 2020 15:18:00 -0500 https://ca.proactiveinvestors.com/companies/news/912787/cytodyn-links-up-with-chinese-medical-services-firm-to-utilize-leronlimab-against-the-coronavirus-912787.html CytoDyn files Phase 2 basket trial with lead drug leronlimab for treating all solid cancer tumors https://ca.proactiveinvestors.com/companies/news/912343/cytodyn-files-phase-2-basket-trial-with-lead-drug-leronlimab-for-treating-all-solid-cancer-tumors-912343.html Thu, 06 Feb 2020 13:09:00 -0500 https://ca.proactiveinvestors.com/companies/news/912343/cytodyn-files-phase-2-basket-trial-with-lead-drug-leronlimab-for-treating-all-solid-cancer-tumors-912343.html CytoDyn looks to schedule emergency Type C meeting with FDA on back of new breast cancer data https://ca.proactiveinvestors.com/companies/news/912007/cytodyn-looks-to-schedule-emergency-type-c-meeting-with-fda-on-back-of-new-breast-cancer-data-912007.html Fri, 31 Jan 2020 20:58:00 -0500 https://ca.proactiveinvestors.com/companies/news/912007/cytodyn-looks-to-schedule-emergency-type-c-meeting-with-fda-on-back-of-new-breast-cancer-data-912007.html NA Proactive news snapshot: Gevo, American Manganese, Hillcrest Petroleum, CytoDyn UPDATE ... https://ca.proactiveinvestors.com/companies/news/911993/na-proactive-news-snapshot-gevo-american-manganese-hillcrest-petroleum-cytodyn-update--911993.html Fri, 31 Jan 2020 17:30:00 -0500 https://ca.proactiveinvestors.com/companies/news/911993/na-proactive-news-snapshot-gevo-american-manganese-hillcrest-petroleum-cytodyn-update--911993.html CytoDyn to request an emergency Type C meeting with FDA to enroll 50 patients with solid cancer tumors https://ca.proactiveinvestors.com/companies/news/911982/cytodyn-to-request-an-emergency-type-c-meeting-with-fda-to-enroll-50-patients-with-solid-cancer-tumors-911982.html Fri, 31 Jan 2020 14:03:00 -0500 https://ca.proactiveinvestors.com/companies/news/911982/cytodyn-to-request-an-emergency-type-c-meeting-with-fda-to-enroll-50-patients-with-solid-cancer-tumors-911982.html NA Proactive news snapshot: BioLargo, Arizona Silver, NexTech AR Solutions, Silvercorp Metals UPDATE … https://ca.proactiveinvestors.com/companies/news/911676/na-proactive-news-snapshot-biolargo-arizona-silver-nextech-ar-solutions-silvercorp-metals-update--911676.html Tue, 28 Jan 2020 22:05:00 -0500 https://ca.proactiveinvestors.com/companies/news/911676/na-proactive-news-snapshot-biolargo-arizona-silver-nextech-ar-solutions-silvercorp-metals-update--911676.html CytoDyn set to explore lead drug leronlimab to combat killer Coronavirus https://ca.proactiveinvestors.com/companies/news/911667/cytodyn-set-to-explore-lead-drug-leronlimab-to-combat-killer-coronavirus-911667.html Tue, 28 Jan 2020 19:41:00 -0500 https://ca.proactiveinvestors.com/companies/news/911667/cytodyn-set-to-explore-lead-drug-leronlimab-to-combat-killer-coronavirus-911667.html CytoDyn to present HIV prevention data at HIV research meeting in Boston https://ca.proactiveinvestors.com/companies/news/911583/cytodyn-to-present-hiv-prevention-data-at-hiv-research-meeting-in-boston-911583.html Mon, 27 Jan 2020 17:52:00 -0500 https://ca.proactiveinvestors.com/companies/news/911583/cytodyn-to-present-hiv-prevention-data-at-hiv-research-meeting-in-boston-911583.html CytoDyn to showcase leronlimab's HIV-prevention potential at Boston medical conference https://ca.proactiveinvestors.com/companies/news/911559/cytodyn-to-showcase-leronlimab-s-hiv-prevention-potential-at-boston-medical-conference-911559.html Mon, 27 Jan 2020 13:46:00 -0500 https://ca.proactiveinvestors.com/companies/news/911559/cytodyn-to-showcase-leronlimab-s-hiv-prevention-potential-at-boston-medical-conference-911559.html CytoDyn brings on Yahoo!, Shutterfly veteran law expert https://ca.proactiveinvestors.com/companies/news/911390/cytodyn-brings-on-yahoo-shutterfly-veteran-law-expert-911390.html Thu, 23 Jan 2020 14:30:00 -0500 https://ca.proactiveinvestors.com/companies/news/911390/cytodyn-brings-on-yahoo-shutterfly-veteran-law-expert-911390.html CytoDyn reveals more promising results from its clinical trials in breast cancer https://ca.proactiveinvestors.com/companies/news/911287/cytodyn-reveals-more-promising-results-from-its-clinical-trials-in-breast-cancer-911287.html Wed, 22 Jan 2020 18:47:00 -0500 https://ca.proactiveinvestors.com/companies/news/911287/cytodyn-reveals-more-promising-results-from-its-clinical-trials-in-breast-cancer-911287.html CytoDyn’s impressive run continues for leronlimab in metastatic triple-negative breast cancer and metastatic breast cancer https://ca.proactiveinvestors.com/companies/news/911268/cytodyns-impressive-run-continues-for-leronlimab-in-metastatic-triple-negative-breast-cancer-and-metastatic-breast-cancer-911268.html Wed, 22 Jan 2020 14:20:00 -0500 https://ca.proactiveinvestors.com/companies/news/911268/cytodyns-impressive-run-continues-for-leronlimab-in-metastatic-triple-negative-breast-cancer-and-metastatic-breast-cancer-911268.html CytoDyn taps former Sarepta Therapeutics COO to its board of directors https://ca.proactiveinvestors.com/companies/news/911163/cytodyn-taps-former-sarepta-therapeutics-coo-to-its-board-of-directors-911163.html Tue, 21 Jan 2020 14:32:00 -0500 https://ca.proactiveinvestors.com/companies/news/911163/cytodyn-taps-former-sarepta-therapeutics-coo-to-its-board-of-directors-911163.html CytoDyn files for breakthrough therapy status in metastatic triple-negative breast cancer https://ca.proactiveinvestors.com/companies/news/910864/cytodyn-files-for-breakthrough-therapy-status-in-metastatic-triple-negative-breast-cancer-910864.html Thu, 16 Jan 2020 21:09:00 -0500 https://ca.proactiveinvestors.com/companies/news/910864/cytodyn-files-for-breakthrough-therapy-status-in-metastatic-triple-negative-breast-cancer-910864.html CytoDyn files for breakthrough therapy status for leronlimab in metastatic triple-negative breast cancer https://ca.proactiveinvestors.com/companies/news/910478/cytodyn-files-for-breakthrough-therapy-status-for-leronlimab-in-metastatic-triple-negative-breast-cancer-910478.html Mon, 13 Jan 2020 19:20:00 -0500 https://ca.proactiveinvestors.com/companies/news/910478/cytodyn-files-for-breakthrough-therapy-status-for-leronlimab-in-metastatic-triple-negative-breast-cancer-910478.html CytoDyn reports early but strong clinical responses for two patients https://ca.proactiveinvestors.com/companies/news/910046/cytodyn-reports-early-but-strong-clinical-responses-for-two-patients-910046.html Mon, 06 Jan 2020 17:02:00 -0500 https://ca.proactiveinvestors.com/companies/news/910046/cytodyn-reports-early-but-strong-clinical-responses-for-two-patients-910046.html NA Proactive news snapshot: Social Life Network, GlobeX Data, Oregenesis, American Manganese UPDATE ... https://ca.proactiveinvestors.com/companies/news/909740/na-proactive-news-snapshot-social-life-network-globex-data-oregenesis-american-manganese-update--909740.html Mon, 23 Dec 2019 21:00:00 -0500 https://ca.proactiveinvestors.com/companies/news/909740/na-proactive-news-snapshot-social-life-network-globex-data-oregenesis-american-manganese-update--909740.html CytoDyn’s leronlimab sees strong positive clinical responses in two patients with metastatic breast cancer and mTNBC https://ca.proactiveinvestors.com/companies/news/909739/cytodyns-leronlimab-sees-strong-positive-clinical-responses-in-two-patients-with-metastatic-breast-cancer-and-mtnbc-909739.html Mon, 23 Dec 2019 12:59:00 -0500 https://ca.proactiveinvestors.com/companies/news/909739/cytodyns-leronlimab-sees-strong-positive-clinical-responses-in-two-patients-with-metastatic-breast-cancer-and-mtnbc-909739.html CytoDyn soars after partnering with Vyera Pharmaceuticals to commercialize leronlimab in US to treat HIV https://ca.proactiveinvestors.com/companies/news/909402/cytodyn-soars-after-partnering-with-vyera-pharmaceuticals-to-commercialize-leronlimab-in-us-to-treat-hiv-909402.html Wed, 18 Dec 2019 20:45:00 -0500 https://ca.proactiveinvestors.com/companies/news/909402/cytodyn-soars-after-partnering-with-vyera-pharmaceuticals-to-commercialize-leronlimab-in-us-to-treat-hiv-909402.html CytoDyn lands commercialization agreement with Vyera Pharmaceuticals to sell leronlimab to treat HIV https://ca.proactiveinvestors.com/companies/news/909476/cytodyn-lands-commercialization-agreement-with-vyera-pharmaceuticals-to-sell-leronlimab-to-treat-hiv-909476.html Wed, 18 Dec 2019 17:36:00 -0500 https://ca.proactiveinvestors.com/companies/news/909476/cytodyn-lands-commercialization-agreement-with-vyera-pharmaceuticals-to-sell-leronlimab-to-treat-hiv-909476.html CytoDyn offers update on leronlimab following encouraging results on breast cancer trial https://ca.proactiveinvestors.com/companies/news/908874/cytodyn-offers-update-on-leronlimab-following-encouraging-results-on-breast-cancer-trial-908874.html Tue, 10 Dec 2019 17:52:00 -0500 https://ca.proactiveinvestors.com/companies/news/908874/cytodyn-offers-update-on-leronlimab-following-encouraging-results-on-breast-cancer-trial-908874.html NA Proactive news snapshot: CUI Global, Carube Copper, CleanSpark, eWellness Healthcare UPDATE … https://ca.proactiveinvestors.com/companies/news/908367/na-proactive-news-snapshot-cui-global-carube-copper-cleanspark-ewellness-healthcare-update--908367.html Tue, 03 Dec 2019 21:30:00 -0500 https://ca.proactiveinvestors.com/companies/news/908367/na-proactive-news-snapshot-cui-global-carube-copper-cleanspark-ewellness-healthcare-update--908367.html CytoDyn reveals positive data on metastatic triple-negative breast cancer trial https://ca.proactiveinvestors.com/companies/news/908383/cytodyn-reveals-positive-data-on-metastatic-triple-negative-breast-cancer-trial-908383.html Tue, 03 Dec 2019 17:52:00 -0500 https://ca.proactiveinvestors.com/companies/news/908383/cytodyn-reveals-positive-data-on-metastatic-triple-negative-breast-cancer-trial-908383.html CytoDyn sees positive results as first triple-negative breast cancer patient treated with leronlimab https://ca.proactiveinvestors.com/companies/news/908359/cytodyn-sees-positive-results-as-first-triple-negative-breast-cancer-patient-treated-with-leronlimab-908359.html Tue, 03 Dec 2019 14:09:00 -0500 https://ca.proactiveinvestors.com/companies/news/908359/cytodyn-sees-positive-results-as-first-triple-negative-breast-cancer-patient-treated-with-leronlimab-908359.html CytoDyn’s positive preclinical data supports leronlimab as treatment for non-alcoholic fatty liver disease https://ca.proactiveinvestors.com/companies/news/907560/cytodyns-positive-preclinical-data-supports-leronlimab-as-treatment-for-non-alcoholic-fatty-liver-disease-907560.html Thu, 21 Nov 2019 13:54:00 -0500 https://ca.proactiveinvestors.com/companies/news/907560/cytodyns-positive-preclinical-data-supports-leronlimab-as-treatment-for-non-alcoholic-fatty-liver-disease-907560.html CytoDyn reveals its drug inhibits colon carcinoma metastases to liver and lung in preclinical study https://ca.proactiveinvestors.com/companies/news/907408/cytodyn-reveals-its-drug-inhibits-colon-carcinoma-metastases-to-liver-and-lung-in-preclinical-study-907408.html Tue, 19 Nov 2019 21:23:00 -0500 https://ca.proactiveinvestors.com/companies/news/907408/cytodyn-reveals-its-drug-inhibits-colon-carcinoma-metastases-to-liver-and-lung-in-preclinical-study-907408.html CytoDyn's lead drug leronlimab inhibits colon carcinoma metastases to liver and lung in preclinical studies https://ca.proactiveinvestors.com/companies/news/907367/cytodyn-s-lead-drug-leronlimab-inhibits-colon-carcinoma-metastases-to-liver-and-lung-in-preclinical-studies-907367.html Tue, 19 Nov 2019 13:11:00 -0500 https://ca.proactiveinvestors.com/companies/news/907367/cytodyn-s-lead-drug-leronlimab-inhibits-colon-carcinoma-metastases-to-liver-and-lung-in-preclinical-studies-907367.html Independent data on CytoDyn’s leronlimab drug to be presented at the CROI conference in March in Boston https://ca.proactiveinvestors.com/companies/news/907271/independent-data-on-cytodyns-leronlimab-drug-to-be-presented-at-the-croi-conference-in-march-in-boston-907271.html Mon, 18 Nov 2019 12:58:00 -0500 https://ca.proactiveinvestors.com/companies/news/907271/independent-data-on-cytodyns-leronlimab-drug-to-be-presented-at-the-croi-conference-in-march-in-boston-907271.html CytoDyn appoints finance veteran Craig S Eastwood as chief finance officer https://ca.proactiveinvestors.com/companies/news/907081/cytodyn-appoints-finance-veteran-craig-s-eastwood-as-chief-finance-officer-907081.html Thu, 14 Nov 2019 12:59:00 -0500 https://ca.proactiveinvestors.com/companies/news/907081/cytodyn-appoints-finance-veteran-craig-s-eastwood-as-chief-finance-officer-907081.html NA Proactive news snapshot: Dyadic International, Biocept, Aftermath Silver, Duos Technologies UPDATE … https://ca.proactiveinvestors.com/companies/news/906967/na-proactive-news-snapshot-dyadic-international-biocept-aftermath-silver-duos-technologies-update--906967.html Wed, 13 Nov 2019 22:10:00 -0500 https://ca.proactiveinvestors.com/companies/news/906967/na-proactive-news-snapshot-dyadic-international-biocept-aftermath-silver-duos-technologies-update--906967.html CytoDyn receives IRB approval to treat triple-negative breast cancer patients in expanded access program https://ca.proactiveinvestors.com/companies/news/906995/cytodyn-receives-irb-approval-to-treat-triple-negative-breast-cancer-patients-in-expanded-access-program-906995.html Wed, 13 Nov 2019 17:20:00 -0500 https://ca.proactiveinvestors.com/companies/news/906995/cytodyn-receives-irb-approval-to-treat-triple-negative-breast-cancer-patients-in-expanded-access-program-906995.html CytoDyn wins IRB approval to give leronlimab to triple-negative breast cancer patients on compassionate grounds https://ca.proactiveinvestors.com/companies/news/906965/cytodyn-wins-irb-approval-to-give-leronlimab-to-triple-negative-breast-cancer-patients-on-compassionate-grounds-906965.html Wed, 13 Nov 2019 12:51:00 -0500 https://ca.proactiveinvestors.com/companies/news/906965/cytodyn-wins-irb-approval-to-give-leronlimab-to-triple-negative-breast-cancer-patients-on-compassionate-grounds-906965.html CytoDyn CEO says leronlimab shrunk tumor in first triple-negative breast cancer patient https://ca.proactiveinvestors.com/companies/news/906895/cytodyn-ceo-says-leronlimab-shrunk-tumor-in-first-triple-negative-breast-cancer-patient-906895.html Tue, 12 Nov 2019 19:42:00 -0500 https://ca.proactiveinvestors.com/companies/news/906895/cytodyn-ceo-says-leronlimab-shrunk-tumor-in-first-triple-negative-breast-cancer-patient-906895.html CytoDyn reports positive results from first patient in triple-negative breast cancer drug leronlimab trial https://ca.proactiveinvestors.com/companies/news/906857/cytodyn-reports-positive-results-from-first-patient-in-triple-negative-breast-cancer-drug-leronlimab-trial-906857.html Tue, 12 Nov 2019 13:44:00 -0500 https://ca.proactiveinvestors.com/companies/news/906857/cytodyn-reports-positive-results-from-first-patient-in-triple-negative-breast-cancer-drug-leronlimab-trial-906857.html CytoDyn CEO addresses share price activity, and upcoming milestones https://ca.proactiveinvestors.com/companies/news/905762/cytodyn-ceo-addresses-share-price-activity-and-upcoming-milestones-905762.html Mon, 28 Oct 2019 17:34:00 -0400 https://ca.proactiveinvestors.com/companies/news/905762/cytodyn-ceo-addresses-share-price-activity-and-upcoming-milestones-905762.html CytoDyn CEO says firm can be one of the top biotech companies in the world, pending clinical success https://ca.proactiveinvestors.com/companies/news/904513/cytodyn-ceo-says-firm-can-be-one-of-the-top-biotech-companies-in-the-world-pending-clinical-success-904513.html Wed, 09 Oct 2019 16:52:00 -0400 https://ca.proactiveinvestors.com/companies/news/904513/cytodyn-ceo-says-firm-can-be-one-of-the-top-biotech-companies-in-the-world-pending-clinical-success-904513.html CytoDyn wins FDA clearance to begin Phase 2 trial of its drug leronlimab in patients with NASH https://ca.proactiveinvestors.com/companies/news/904002/cytodyn-wins-fda-clearance-to-begin-phase-2-trial-of-its-drug-leronlimab-in-patients-with-nash-904002.html Wed, 02 Oct 2019 14:50:00 -0400 https://ca.proactiveinvestors.com/companies/news/904002/cytodyn-wins-fda-clearance-to-begin-phase-2-trial-of-its-drug-leronlimab-in-patients-with-nash-904002.html NA Proactive news snapshot: Mandalay Resources, Acasti Pharma, EnWave, NetCents Technology, GlobeX Data UPDATE … https://ca.proactiveinvestors.com/companies/news/903792/na-proactive-news-snapshot-mandalay-resources-acasti-pharma-enwave-netcents-technology-globex-data-update--903792.html Mon, 30 Sep 2019 21:30:00 -0400 https://ca.proactiveinvestors.com/companies/news/903792/na-proactive-news-snapshot-mandalay-resources-acasti-pharma-enwave-netcents-technology-globex-data-update--903792.html CytoDyn's triple-negative breast cancer drug leronlimab given to first patient in clinical trial https://ca.proactiveinvestors.com/companies/news/903769/cytodyn-s-triple-negative-breast-cancer-drug-leronlimab-given-to-first-patient-in-clinical-trial-903769.html Mon, 30 Sep 2019 20:20:00 -0400 https://ca.proactiveinvestors.com/companies/news/903769/cytodyn-s-triple-negative-breast-cancer-drug-leronlimab-given-to-first-patient-in-clinical-trial-903769.html CytoDyn has multiple shots on goal with its flagship drug leronlimab as cure for HIV, various cancers https://ca.proactiveinvestors.com/companies/news/902994/cytodyn-has-multiple-shots-on-goal-with-its-flagship-drug-leronlimab-as-cure-for-hiv-various-cancers-902994.html Thu, 19 Sep 2019 11:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/902994/cytodyn-has-multiple-shots-on-goal-with-its-flagship-drug-leronlimab-as-cure-for-hiv-various-cancers-902994.html CytoDyn CEO discusses findings in Yale University report, updates on licensing agreement initiatives https://ca.proactiveinvestors.com/companies/news/902985/cytodyn-ceo-discusses-findings-in-yale-university-report-updates-on-licensing-agreement-initiatives-902985.html Wed, 18 Sep 2019 16:54:00 -0400 https://ca.proactiveinvestors.com/companies/news/902985/cytodyn-ceo-discusses-findings-in-yale-university-report-updates-on-licensing-agreement-initiatives-902985.html NA Proactive news snapshot: Lydian International, CytoDyn, Pure Gold Mining, XPhyto Therapeutics UPDATE … https://ca.proactiveinvestors.com/companies/news/902315/na-proactive-news-snapshot-lydian-international-cytodyn-pure-gold-mining-xphyto-therapeutics-update--902315.html Mon, 09 Sep 2019 21:15:00 -0400 https://ca.proactiveinvestors.com/companies/news/902315/na-proactive-news-snapshot-lydian-international-cytodyn-pure-gold-mining-xphyto-therapeutics-update--902315.html CytoDyn CEO says FDA OK to begin Phase 2 to treat colon cancer just 'tip of the iceberg' https://ca.proactiveinvestors.com/companies/news/902326/cytodyn-ceo-says-fda-ok-to-begin-phase-2-to-treat-colon-cancer-just--tip-of-the-iceberg--902326.html Mon, 09 Sep 2019 16:23:00 -0400 https://ca.proactiveinvestors.com/companies/news/902326/cytodyn-ceo-says-fda-ok-to-begin-phase-2-to-treat-colon-cancer-just--tip-of-the-iceberg--902326.html CytoDyn wins FDA approval for Phase 2 Study of leronlimab and Regorafenib as combo therapy https://ca.proactiveinvestors.com/companies/news/902297/cytodyn-wins-fda-approval-for-phase-2-study-of-leronlimab-and-regorafenib-as-combo-therapy-902297.html Mon, 09 Sep 2019 11:40:00 -0400 https://ca.proactiveinvestors.com/companies/news/902297/cytodyn-wins-fda-approval-for-phase-2-study-of-leronlimab-and-regorafenib-as-combo-therapy-902297.html NA Proactive news snapshot: Telson Mining, WeedMD, Ozop Surgical, PyroGenesis Canada, Social Life Network UPDATE … https://ca.proactiveinvestors.com/companies/news/902034/na-proactive-news-snapshot-telson-mining-weedmd-ozop-surgical-pyrogenesis-canada-social-life-network-update---902034.html Wed, 04 Sep 2019 21:05:00 -0400 https://ca.proactiveinvestors.com/companies/news/902034/na-proactive-news-snapshot-telson-mining-weedmd-ozop-surgical-pyrogenesis-canada-social-life-network-update---902034.html CytoDyn moving towards Phase 2 trial to treat NASH with flagship leronlimab drug https://ca.proactiveinvestors.com/companies/news/902047/cytodyn-moving-towards-phase-2-trial-to-treat-nash-with-flagship-leronlimab-drug-902047.html Wed, 04 Sep 2019 17:31:00 -0400 https://ca.proactiveinvestors.com/companies/news/902047/cytodyn-moving-towards-phase-2-trial-to-treat-nash-with-flagship-leronlimab-drug-902047.html CytoDyn files IND and Phase 2 protocol with FDA for use of leronlimab in treating NASH https://ca.proactiveinvestors.com/companies/news/902021/cytodyn-files-ind-and-phase-2-protocol-with-fda-for-use-of-leronlimab-in-treating-nash-902021.html Wed, 04 Sep 2019 11:40:00 -0400 https://ca.proactiveinvestors.com/companies/news/902021/cytodyn-files-ind-and-phase-2-protocol-with-fda-for-use-of-leronlimab-in-treating-nash-902021.html CytoDyn reveals adjustment to its HIV monotherapy treatment in 'major' announcement https://ca.proactiveinvestors.com/companies/news/901575/cytodyn-reveals-adjustment-to-its-hiv-monotherapy-treatment-in--major--announcement-901575.html Tue, 27 Aug 2019 17:43:00 -0400 https://ca.proactiveinvestors.com/companies/news/901575/cytodyn-reveals-adjustment-to-its-hiv-monotherapy-treatment-in--major--announcement-901575.html CytoDyn sees 'strong result' in leronlimab dose escalation monotherapy trial to treat HIV https://ca.proactiveinvestors.com/companies/news/900784/cytodyn-sees--strong-result--in-leronlimab-dose-escalation-monotherapy-trial-to-treat-hiv-900784.html Wed, 14 Aug 2019 17:46:00 -0400 https://ca.proactiveinvestors.com/companies/news/900784/cytodyn-sees--strong-result--in-leronlimab-dose-escalation-monotherapy-trial-to-treat-hiv-900784.html CytoDyn reports positive results from dose escalating trial with lead drug leronlimab as a HIV monotherapy https://ca.proactiveinvestors.com/companies/news/900775/cytodyn-reports-positive-results-from-dose-escalating-trial-with-lead-drug-leronlimab-as-a-hiv-monotherapy-900775.html Wed, 14 Aug 2019 15:15:00 -0400 https://ca.proactiveinvestors.com/companies/news/900775/cytodyn-reports-positive-results-from-dose-escalating-trial-with-lead-drug-leronlimab-as-a-hiv-monotherapy-900775.html CytoDyn looks to FDA to green light Phase 2 trials of leronlimab to treat colon cancer https://ca.proactiveinvestors.com/companies/news/900402/cytodyn-looks-to-fda-to-green-light-phase-2-trials-of-leronlimab-to-treat-colon-cancer-900402.html Thu, 08 Aug 2019 18:41:00 -0400 https://ca.proactiveinvestors.com/companies/news/900402/cytodyn-looks-to-fda-to-green-light-phase-2-trials-of-leronlimab-to-treat-colon-cancer-900402.html CytoDyn files Phase 2 protocol with FDA for use of leronlimab and regorafenib as combo therapy for metastatic colorectal cancer https://ca.proactiveinvestors.com/companies/news/900381/cytodyn-files-phase-2-protocol-with-fda-for-use-of-leronlimab-and-regorafenib-as-combo-therapy-for-metastatic-colorectal-cancer-900381.html Thu, 08 Aug 2019 13:25:00 -0400 https://ca.proactiveinvestors.com/companies/news/900381/cytodyn-files-phase-2-protocol-with-fda-for-use-of-leronlimab-and-regorafenib-as-combo-therapy-for-metastatic-colorectal-cancer-900381.html CytoDyn marks major milestone for its leronlimab drug with first step into field of cancer https://ca.proactiveinvestors.com/companies/news/900209/cytodyn-marks-major-milestone-for-its-leronlimab-drug-with-first-step-into-field-of-cancer-900209.html Tue, 06 Aug 2019 18:55:00 -0400 https://ca.proactiveinvestors.com/companies/news/900209/cytodyn-marks-major-milestone-for-its-leronlimab-drug-with-first-step-into-field-of-cancer-900209.html CytoDyn injects first breast cancer patient with its flagship therapy https://ca.proactiveinvestors.com/companies/news/900239/cytodyn-injects-first-breast-cancer-patient-with-its-flagship-therapy-900239.html Tue, 06 Aug 2019 17:53:00 -0400 https://ca.proactiveinvestors.com/companies/news/900239/cytodyn-injects-first-breast-cancer-patient-with-its-flagship-therapy-900239.html FDA waives application fees for CytoDyn's BLA filing for HIV drug Leronlimab https://ca.proactiveinvestors.com/companies/news/900118/fda-waives-application-fees-for-cytodyn-s-bla-filing-for-hiv-drug-leronlimab-900118.html Mon, 05 Aug 2019 11:45:00 -0400 https://ca.proactiveinvestors.com/companies/news/900118/fda-waives-application-fees-for-cytodyn-s-bla-filing-for-hiv-drug-leronlimab-900118.html CytoDyn to apply to enter phase 2 clinical studies with PRO140 to treat colon cancer https://ca.proactiveinvestors.com/companies/news/314314/cytodyn-to-apply-to-enter-phase-2-clinical-studies-with-pro140-to-treat-colon-cancer-14314.html Fri, 02 Aug 2019 16:58:00 -0400 https://ca.proactiveinvestors.com/companies/news/314314/cytodyn-to-apply-to-enter-phase-2-clinical-studies-with-pro140-to-treat-colon-cancer-14314.html CytoDyn successfully completes preclinical colon cancer treatment studies https://ca.proactiveinvestors.com/companies/news/224921/cytodyn-successfully-completes-preclinical-colon-cancer-treatment-studies-224921.html Fri, 02 Aug 2019 12:35:00 -0400 https://ca.proactiveinvestors.com/companies/news/224921/cytodyn-successfully-completes-preclinical-colon-cancer-treatment-studies-224921.html CytoDyn to begin generating revenue with IncellDX licensing agreement https://ca.proactiveinvestors.com/companies/news/314224/cytodyn-to-begin-generating-revenue-with-incelldx-licensing-agreement-14224.html Fri, 26 Jul 2019 16:44:00 -0400 https://ca.proactiveinvestors.com/companies/news/314224/cytodyn-to-begin-generating-revenue-with-incelldx-licensing-agreement-14224.html CytoDyn inks exclusive licensing pact with IncellDX to supply non-commercial grade PRO 140 antibody https://ca.proactiveinvestors.com/companies/news/224569/cytodyn-inks-exclusive-licensing-pact-with-incelldx-to-supply-non-commercial-grade-pro-140-antibody-224569.html Fri, 26 Jul 2019 12:20:00 -0400 https://ca.proactiveinvestors.com/companies/news/224569/cytodyn-inks-exclusive-licensing-pact-with-incelldx-to-supply-non-commercial-grade-pro-140-antibody-224569.html CytoDyn armed with 'key test' to guide its near-term discussions with the FDA https://ca.proactiveinvestors.com/companies/news/314211/cytodyn-armed-with--key-test--to-guide-its-near-term-discussions-with-the-fda-14211.html Thu, 25 Jul 2019 19:42:00 -0400 https://ca.proactiveinvestors.com/companies/news/314211/cytodyn-armed-with--key-test--to-guide-its-near-term-discussions-with-the-fda-14211.html CytoDyn finalizes key test which will guide discussions with FDA on lead drug leronlimab as a monotherapy https://ca.proactiveinvestors.com/companies/news/224511/cytodyn-finalizes-key-test-which-will-guide-discussions-with-fda-on-lead-drug-leronlimab-as-a-monotherapy-224511.html Thu, 25 Jul 2019 12:30:00 -0400 https://ca.proactiveinvestors.com/companies/news/224511/cytodyn-finalizes-key-test-which-will-guide-discussions-with-fda-on-lead-drug-leronlimab-as-a-monotherapy-224511.html CytoDyn brings on senior science advisor to develop leronlimab to treat HIV PrEP https://ca.proactiveinvestors.com/companies/news/314017/cytodyn-brings-on-senior-science-advisor-to-develop-leronlimab-to-treat-hiv-prep-14017.html Mon, 08 Jul 2019 18:15:00 -0400 https://ca.proactiveinvestors.com/companies/news/314017/cytodyn-brings-on-senior-science-advisor-to-develop-leronlimab-to-treat-hiv-prep-14017.html CytoDyn taps top AIDS research expert Jonah Sacha as senior science advisor https://ca.proactiveinvestors.com/companies/news/223507/cytodyn-taps-top-aids-research-expert-jonah-sacha-as-senior-science-advisor-223507.html Mon, 08 Jul 2019 11:36:00 -0400 https://ca.proactiveinvestors.com/companies/news/223507/cytodyn-taps-top-aids-research-expert-jonah-sacha-as-senior-science-advisor-223507.html CytoDyn anticipates near-term revenue from cell diagnostic company IncellDX https://ca.proactiveinvestors.com/companies/news/313958/cytodyn-anticipates-near-term-revenue-from-cell-diagnostic-company-incelldx-13958.html Tue, 02 Jul 2019 18:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/313958/cytodyn-anticipates-near-term-revenue-from-cell-diagnostic-company-incelldx-13958.html CytoDyn eyes revenue in August from deal to supply IncellDX with its non-commercial grade PRO 140 https://ca.proactiveinvestors.com/companies/news/223141/cytodyn-eyes-revenue-in-august-from-deal-to-supply-incelldx-with-its-non-commercial-grade-pro-140-223141.html Mon, 01 Jul 2019 18:04:00 -0400 https://ca.proactiveinvestors.com/companies/news/223141/cytodyn-eyes-revenue-in-august-from-deal-to-supply-incelldx-with-its-non-commercial-grade-pro-140-223141.html CytoDyn to meet with FDA to discuss prostate cancer-detection test https://ca.proactiveinvestors.com/companies/news/313850/cytodyn-to-meet-with-fda-to-discuss-prostate-cancer-detection-test-13850.html Mon, 24 Jun 2019 17:22:00 -0400 https://ca.proactiveinvestors.com/companies/news/313850/cytodyn-to-meet-with-fda-to-discuss-prostate-cancer-detection-test-13850.html CytoDyn to meet with FDA on August 28 to discuss clearance of prostate cancer-detection test https://ca.proactiveinvestors.com/companies/news/222675/cytodyn-to-meet-with-fda-on-august-28-to-discuss-clearance-of-prostate-cancer-detection-test-222675.html Mon, 24 Jun 2019 11:42:00 -0400 https://ca.proactiveinvestors.com/companies/news/222675/cytodyn-to-meet-with-fda-on-august-28-to-discuss-clearance-of-prostate-cancer-detection-test-222675.html CytoDyn to meet with FDA on prostate-cancer test, applies HIV screening test to monotherapy trial https://ca.proactiveinvestors.com/companies/news/313837/cytodyn-to-meet-with-fda-on-prostate-cancer-test-applies-hiv-screening-test-to-monotherapy-trial-13837.html Fri, 21 Jun 2019 17:12:00 -0400 https://ca.proactiveinvestors.com/companies/news/313837/cytodyn-to-meet-with-fda-on-prostate-cancer-test-applies-hiv-screening-test-to-monotherapy-trial-13837.html CytoDyn requests FDA meeting to discuss clearance of prostate cancer-detection test https://ca.proactiveinvestors.com/companies/news/222434/cytodyn-requests-fda-meeting-to-discuss-clearance-of-prostate-cancer-detection-test-222434.html Wed, 19 Jun 2019 15:20:00 -0400 https://ca.proactiveinvestors.com/companies/news/222434/cytodyn-requests-fda-meeting-to-discuss-clearance-of-prostate-cancer-detection-test-222434.html Breakthrough test predicts which HIV patients will respond to CytoDyn's leronlimab as a monotherapy https://ca.proactiveinvestors.com/companies/news/222333/breakthrough-test-predicts-which-hiv-patients-will-respond-to-cytodyn-s-leronlimab-as-a-monotherapy-222333.html Tue, 18 Jun 2019 12:04:00 -0400 https://ca.proactiveinvestors.com/companies/news/222333/breakthrough-test-predicts-which-hiv-patients-will-respond-to-cytodyn-s-leronlimab-as-a-monotherapy-222333.html CytoDyn CEO talks about latest HIV trial featuring its flagship drug, leronlimab https://ca.proactiveinvestors.com/companies/news/313768/cytodyn-ceo-talks-about-latest-hiv-trial-featuring-its-flagship-drug-leronlimab-13768.html Mon, 17 Jun 2019 17:11:00 -0400 https://ca.proactiveinvestors.com/companies/news/313768/cytodyn-ceo-talks-about-latest-hiv-trial-featuring-its-flagship-drug-leronlimab-13768.html Thai Red Cross AIDS Research Centre to conduct a pre-exposure prophylaxis clinical HIV trial of CytoDyn’s leronlimab https://ca.proactiveinvestors.com/companies/news/222241/thai-red-cross-aids-research-centre-to-conduct-a-pre-exposure-prophylaxis-clinical-hiv-trial-of-cytodyns-leronlimab-222241.html Mon, 17 Jun 2019 13:10:00 -0400 https://ca.proactiveinvestors.com/companies/news/222241/thai-red-cross-aids-research-centre-to-conduct-a-pre-exposure-prophylaxis-clinical-hiv-trial-of-cytodyns-leronlimab-222241.html CytoDyn raises over $12M as it looks to commercialize lead drug leronlimab https://ca.proactiveinvestors.com/companies/news/222151/cytodyn-raises-over-12m-as-it-looks-to-commercialize-lead-drug-leronlimab-222151.html Fri, 14 Jun 2019 12:05:00 -0400 https://ca.proactiveinvestors.com/companies/news/222151/cytodyn-raises-over-12m-as-it-looks-to-commercialize-lead-drug-leronlimab-222151.html CytoDyn to present at ASM Microbe demonstrating Leronlimab's potency in HIV patients with multiple drug resistance https://ca.proactiveinvestors.com/companies/news/222060/cytodyn-to-present-at-asm-microbe-demonstrating-leronlimab-s-potency-in-hiv-patients-with-multiple-drug-resistance-222060.html Thu, 13 Jun 2019 12:55:00 -0400 https://ca.proactiveinvestors.com/companies/news/222060/cytodyn-to-present-at-asm-microbe-demonstrating-leronlimab-s-potency-in-hiv-patients-with-multiple-drug-resistance-222060.html CytoDyn CEO responds to share price rise as investors get excited about leronlimab https://ca.proactiveinvestors.com/companies/news/313713/cytodyn-ceo-responds-to-share-price-rise-as-investors-get-excited-about-leronlimab-13713.html Wed, 12 Jun 2019 18:57:00 -0400 https://ca.proactiveinvestors.com/companies/news/313713/cytodyn-ceo-responds-to-share-price-rise-as-investors-get-excited-about-leronlimab-13713.html CytoDyn stock jumps as investor focus shifts to leronlimab as CymaBay flames out https://ca.proactiveinvestors.com/companies/news/221916/cytodyn-stock-jumps-as-investor-focus-shifts-to-leronlimab-as-cymabay-flames-out-221916.html Tue, 11 Jun 2019 20:15:00 -0400 https://ca.proactiveinvestors.com/companies/news/221916/cytodyn-stock-jumps-as-investor-focus-shifts-to-leronlimab-as-cymabay-flames-out-221916.html CytoDyn to meet with FDA to finalize next steps on leronlimab drug trial for HIV https://ca.proactiveinvestors.com/companies/news/313675/cytodyn-to-meet-with-fda-to-finalize-next-steps-on-leronlimab-drug-trial-for-hiv-13675.html Fri, 07 Jun 2019 16:41:00 -0400 https://ca.proactiveinvestors.com/companies/news/313675/cytodyn-to-meet-with-fda-to-finalize-next-steps-on-leronlimab-drug-trial-for-hiv-13675.html CytoDyn to meet with FDA to finalize protocol for pivotal trial of flagship drug leronlimab https://ca.proactiveinvestors.com/companies/news/221730/cytodyn-to-meet-with-fda-to-finalize-protocol-for-pivotal-trial-of-flagship-drug-leronlimab-221730.html Fri, 07 Jun 2019 11:36:00 -0400 https://ca.proactiveinvestors.com/companies/news/221730/cytodyn-to-meet-with-fda-to-finalize-protocol-for-pivotal-trial-of-flagship-drug-leronlimab-221730.html CytoDyn shows value of company lies in their research and technology https://ca.proactiveinvestors.com/companies/news/313600/cytodyn-shows-value-of-company-lies-in-their-research-and-technology-13600.html Wed, 05 Jun 2019 03:19:00 -0400 https://ca.proactiveinvestors.com/companies/news/313600/cytodyn-shows-value-of-company-lies-in-their-research-and-technology-13600.html CytoDyn updates investors on licensing agreement potentials at shareholders meeting https://ca.proactiveinvestors.com/companies/news/313502/cytodyn-updates-investors-on-licensing-agreement-potentials-at-shareholders-meeting-13502.html Tue, 28 May 2019 18:10:00 -0400 https://ca.proactiveinvestors.com/companies/news/313502/cytodyn-updates-investors-on-licensing-agreement-potentials-at-shareholders-meeting-13502.html CytoDyn takes major step forward filing trial protocol for HIV Monotherapy https://ca.proactiveinvestors.com/companies/news/313376/cytodyn-takes-major-step-forward-filing-trial-protocol-for-hiv-monotherapy-13376.html Thu, 16 May 2019 11:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/313376/cytodyn-takes-major-step-forward-filing-trial-protocol-for-hiv-monotherapy-13376.html CytoDyn files pivotal trial protocol with FDA for flagship drug leronlimab as monotherapy for HIV https://ca.proactiveinvestors.com/companies/news/220325/cytodyn-files-pivotal-trial-protocol-with-fda-for-flagship-drug-leronlimab-as-monotherapy-for-hiv-220325.html Wed, 15 May 2019 13:05:00 -0400 https://ca.proactiveinvestors.com/companies/news/220325/cytodyn-files-pivotal-trial-protocol-with-fda-for-flagship-drug-leronlimab-as-monotherapy-for-hiv-220325.html CytoDyn adds new talent to its management team https://ca.proactiveinvestors.com/companies/news/313349/cytodyn-adds-new-talent-to-its-management-team-13349.html Tue, 14 May 2019 19:56:00 -0400 https://ca.proactiveinvestors.com/companies/news/313349/cytodyn-adds-new-talent-to-its-management-team-13349.html CytoDyn announces two new additions to management team https://ca.proactiveinvestors.com/companies/news/220229/cytodyn-announces-two-new-additions-to-management-team-220229.html Tue, 14 May 2019 13:14:00 -0400 https://ca.proactiveinvestors.com/companies/news/220229/cytodyn-announces-two-new-additions-to-management-team-220229.html CytoDyn to begin proof-of-concept studies for leronlimab to treat liver damage caused by NASH https://ca.proactiveinvestors.com/companies/news/313325/cytodyn-to-begin-proof-of-concept-studies-for-leronlimab-to-treat-liver-damage-caused-by-nash-13325.html Mon, 13 May 2019 19:37:00 -0400 https://ca.proactiveinvestors.com/companies/news/313325/cytodyn-to-begin-proof-of-concept-studies-for-leronlimab-to-treat-liver-damage-caused-by-nash-13325.html CytoDyn's flagship drug leronlimab to be tested to prevent fatty liver diease in mice https://ca.proactiveinvestors.com/companies/news/220143/cytodyn-s-flagship-drug-leronlimab-to-be-tested-to-prevent-fatty-liver-diease-in-mice-220143.html Mon, 13 May 2019 13:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/220143/cytodyn-s-flagship-drug-leronlimab-to-be-tested-to-prevent-fatty-liver-diease-in-mice-220143.html CytoDyn reports positive preclinical data, gets FDA's fast-track designation https://ca.proactiveinvestors.com/companies/news/313263/cytodyn-reports-positive-preclinical-data-gets-fda-s-fast-track-designation-13263.html Wed, 08 May 2019 17:05:00 -0400 https://ca.proactiveinvestors.com/companies/news/313263/cytodyn-reports-positive-preclinical-data-gets-fda-s-fast-track-designation-13263.html CytoDyn preclinical data shows leronlimab suppresses breast cancer tumor burden by more than 98% https://ca.proactiveinvestors.com/companies/news/219912/cytodyn-preclinical-data-shows-leronlimab-suppresses-breast-cancer-tumor-burden-by-more-than-98-219912.html Wed, 08 May 2019 16:05:00 -0400 https://ca.proactiveinvestors.com/companies/news/219912/cytodyn-preclinical-data-shows-leronlimab-suppresses-breast-cancer-tumor-burden-by-more-than-98-219912.html CytoDyn sees progress with leronlimab to treat HIV-infected patients https://ca.proactiveinvestors.com/companies/news/313242/cytodyn-sees-progress-with-leronlimab-to-treat-hiv-infected-patients-13242.html Tue, 07 May 2019 18:18:00 -0400 https://ca.proactiveinvestors.com/companies/news/313242/cytodyn-sees-progress-with-leronlimab-to-treat-hiv-infected-patients-13242.html CytoDyn secures fast track FDA designation for leronlimab in treating metastatic triple negative breast cancer https://ca.proactiveinvestors.com/companies/news/219797/cytodyn-secures-fast-track-fda-designation-for-leronlimab-in-treating-metastatic-triple-negative-breast-cancer-219797.html Tue, 07 May 2019 11:56:00 -0400 https://ca.proactiveinvestors.com/companies/news/219797/cytodyn-secures-fast-track-fda-designation-for-leronlimab-in-treating-metastatic-triple-negative-breast-cancer-219797.html CytoDyn sees progress in trial using flagship drug leronlimab to treat HIV-infected patients https://ca.proactiveinvestors.com/companies/news/219718/cytodyn-sees-progress-in-trial-using-flagship-drug-leronlimab-to-treat-hiv-infected-patients-219718.html Mon, 06 May 2019 16:23:00 -0400 https://ca.proactiveinvestors.com/companies/news/219718/cytodyn-sees-progress-in-trial-using-flagship-drug-leronlimab-to-treat-hiv-infected-patients-219718.html Cytodyn has raised over 190 million dollars as they look to commercialize lead drug https://ca.proactiveinvestors.com/companies/news/313213/cytodyn-has-raised-over-190-million-dollars-as-they-look-to-commercialize-lead-drug-13213.html Thu, 02 May 2019 18:58:00 -0400 https://ca.proactiveinvestors.com/companies/news/313213/cytodyn-has-raised-over-190-million-dollars-as-they-look-to-commercialize-lead-drug-13213.html CytoDyn CEO updates timeline for HIV drug, addresses share dilution concerns https://ca.proactiveinvestors.com/companies/news/313008/cytodyn-ceo-updates-timeline-for-hiv-drug-addresses-share-dilution-concerns-13008.html Mon, 15 Apr 2019 18:25:00 -0400 https://ca.proactiveinvestors.com/companies/news/313008/cytodyn-ceo-updates-timeline-for-hiv-drug-addresses-share-dilution-concerns-13008.html CytoDyn teams with Samsung BioLogics, presents key data at cancer research meeting https://ca.proactiveinvestors.com/companies/news/312876/cytodyn-teams-with-samsung-biologics-presents-key-data-at-cancer-research-meeting-12876.html Thu, 04 Apr 2019 18:13:00 -0400 https://ca.proactiveinvestors.com/companies/news/312876/cytodyn-teams-with-samsung-biologics-presents-key-data-at-cancer-research-meeting-12876.html CytoDyn to demonstrate superior potency of leronlimab in HIV patients at ASM Microbe 2019 https://ca.proactiveinvestors.com/companies/news/217969/cytodyn-to-demonstrate-superior-potency-of-leronlimab-in-hiv-patients-at-asm-microbe-2019-217969.html Thu, 04 Apr 2019 11:59:00 -0400 https://ca.proactiveinvestors.com/companies/news/217969/cytodyn-to-demonstrate-superior-potency-of-leronlimab-in-hiv-patients-at-asm-microbe-2019-217969.html CytoDyn forges deal with Samsung BioLogics to make $1B worth of leronlimab to meet expected demand https://ca.proactiveinvestors.com/companies/news/217765/cytodyn-forges-deal-with-samsung-biologics-to-make-1b-worth-of-leronlimab-to-meet-expected-demand-217765.html Tue, 02 Apr 2019 14:30:00 -0400 https://ca.proactiveinvestors.com/companies/news/217765/cytodyn-forges-deal-with-samsung-biologics-to-make-1b-worth-of-leronlimab-to-meet-expected-demand-217765.html CytoDyn to share data on flagship drug leronlimab at the American Association of Cancer Research https://ca.proactiveinvestors.com/companies/news/217645/cytodyn-to-share-data-on-flagship-drug-leronlimab-at-the-american-association-of-cancer-research-217645.html Mon, 01 Apr 2019 07:07:00 -0400 https://ca.proactiveinvestors.com/companies/news/217645/cytodyn-to-share-data-on-flagship-drug-leronlimab-at-the-american-association-of-cancer-research-217645.html CytoDyn more than doubles recovery rate in its monotherapy HIV trial https://ca.proactiveinvestors.com/companies/news/312760/cytodyn-more-than-doubles-recovery-rate-in-its-monotherapy-hiv-trial-12760.html Wed, 27 Mar 2019 20:31:00 -0400 https://ca.proactiveinvestors.com/companies/news/312760/cytodyn-more-than-doubles-recovery-rate-in-its-monotherapy-hiv-trial-12760.html CytoDyn’s monotherapy trial with flagship HIV drug leronlimab exceeds expectations https://ca.proactiveinvestors.com/companies/news/217226/cytodyns-monotherapy-trial-with-flagship-hiv-drug-leronlimab-exceeds-expectations-217226.html Tue, 26 Mar 2019 12:15:00 -0400 https://ca.proactiveinvestors.com/companies/news/217226/cytodyns-monotherapy-trial-with-flagship-hiv-drug-leronlimab-exceeds-expectations-217226.html CytoDyn's HIV drug leromlimab takes a big step forward https://ca.proactiveinvestors.com/companies/news/312632/cytodyn-s-hiv-drug-leromlimab-takes-a-big-step-forward-12632.html Mon, 18 Mar 2019 13:43:00 -0400 https://ca.proactiveinvestors.com/companies/news/312632/cytodyn-s-hiv-drug-leromlimab-takes-a-big-step-forward-12632.html CytoDyn submits first part of biologics license application to FDA for flagship HIV drug leronlimab https://ca.proactiveinvestors.com/companies/news/216644/cytodyn-submits-first-part-of-biologics-license-application-to-fda-for-flagship-hiv-drug-leronlimab-216644.html Mon, 18 Mar 2019 12:02:00 -0400 https://ca.proactiveinvestors.com/companies/news/216644/cytodyn-submits-first-part-of-biologics-license-application-to-fda-for-flagship-hiv-drug-leronlimab-216644.html CytoDyn files for fast-track designation for leronlimab in breast cancer treatment https://ca.proactiveinvestors.com/companies/news/312550/cytodyn-files-for-fast-track-designation-for-leronlimab-in-breast-cancer-treatment-12550.html Mon, 11 Mar 2019 20:35:00 -0400 https://ca.proactiveinvestors.com/companies/news/312550/cytodyn-files-for-fast-track-designation-for-leronlimab-in-breast-cancer-treatment-12550.html CytoDyn announces filing of FDA fast-track application for breast cancer treatment https://ca.proactiveinvestors.com/companies/news/216200/cytodyn-announces-filing-of-fda-fast-track-application-for-breast-cancer-treatment-216200.html Mon, 11 Mar 2019 14:17:00 -0400 https://ca.proactiveinvestors.com/companies/news/216200/cytodyn-announces-filing-of-fda-fast-track-application-for-breast-cancer-treatment-216200.html CytoDyn presents 'stunning' data on treatment of HIV at Seattle conference https://ca.proactiveinvestors.com/companies/news/312530/cytodyn-presents--stunning--data-on-treatment-of-hiv-at-seattle-conference-12530.html Fri, 08 Mar 2019 18:41:00 -0500 https://ca.proactiveinvestors.com/companies/news/312530/cytodyn-presents--stunning--data-on-treatment-of-hiv-at-seattle-conference-12530.html CytoDyn presses forward with HIV treatment after Phase 3 https://ca.proactiveinvestors.com/companies/news/215750/cytodyn-presses-forward-with-hiv-treatment-after-phase-3-215750.html Wed, 06 Mar 2019 19:35:00 -0500 https://ca.proactiveinvestors.com/companies/news/215750/cytodyn-presses-forward-with-hiv-treatment-after-phase-3-215750.html FDA accepted CytoDyn’s request and plan to submit BLA on rolling basis https://ca.proactiveinvestors.com/companies/news/312448/fda-accepted-cytodyns-request-and-plan-to-submit-bla-on-rolling-basis-12448.html Mon, 04 Mar 2019 21:28:00 -0500 https://ca.proactiveinvestors.com/companies/news/312448/fda-accepted-cytodyns-request-and-plan-to-submit-bla-on-rolling-basis-12448.html CytoDyn granted rolling review by FDA for its Biologics License Application for its HIV therapy leronlimab https://ca.proactiveinvestors.com/companies/news/215721/cytodyn-granted-rolling-review-by-fda-for-its-biologics-license-application-for-its-hiv-therapy-leronlimab-215721.html Mon, 04 Mar 2019 12:57:00 -0500 https://ca.proactiveinvestors.com/companies/news/215721/cytodyn-granted-rolling-review-by-fda-for-its-biologics-license-application-for-its-hiv-therapy-leronlimab-215721.html CytoDyn to present data on monoclonal antibody treatment of HIV at Seattle conference https://ca.proactiveinvestors.com/companies/news/215433/cytodyn-to-present-data-on-monoclonal-antibody-treatment-of-hiv-at-seattle-conference-215433.html Wed, 27 Feb 2019 15:22:00 -0500 https://ca.proactiveinvestors.com/companies/news/215433/cytodyn-to-present-data-on-monoclonal-antibody-treatment-of-hiv-at-seattle-conference-215433.html CytoDyn files for Orphan Drug designation to treat triple-negative breast cancer https://ca.proactiveinvestors.com/companies/news/312316/cytodyn-files-for-orphan-drug-designation-to-treat-triple-negative-breast-cancer-12316.html Thu, 21 Feb 2019 20:05:00 -0500 https://ca.proactiveinvestors.com/companies/news/312316/cytodyn-files-for-orphan-drug-designation-to-treat-triple-negative-breast-cancer-12316.html CytoDyn’s leronlimab reduces by more than 98% human breast cancer metastasis in mouse xenografts https://ca.proactiveinvestors.com/companies/news/214963/cytodyns-leronlimab-reduces-by-more-than-98-human-breast-cancer-metastasis-in-mouse-xenografts-214963.html Wed, 20 Feb 2019 13:08:00 -0500 https://ca.proactiveinvestors.com/companies/news/214963/cytodyns-leronlimab-reduces-by-more-than-98-human-breast-cancer-metastasis-in-mouse-xenografts-214963.html CytoDyn to begin preclinical studies with leronlimab for 8 different cancers https://ca.proactiveinvestors.com/companies/news/312292/cytodyn-to-begin-preclinical-studies-with-leronlimab-for-8-different-cancers-12292.html Tue, 19 Feb 2019 21:26:00 -0500 https://ca.proactiveinvestors.com/companies/news/312292/cytodyn-to-begin-preclinical-studies-with-leronlimab-for-8-different-cancers-12292.html CytoDyn to initiate 8 preclinical animal studies with leronlimab for multiple cancers https://ca.proactiveinvestors.com/companies/news/214879/cytodyn-to-initiate-8-preclinical-animal-studies-with-leronlimab-for-multiple-cancers-214879.html Tue, 19 Feb 2019 12:54:00 -0500 https://ca.proactiveinvestors.com/companies/news/214879/cytodyn-to-initiate-8-preclinical-animal-studies-with-leronlimab-for-multiple-cancers-214879.html CytoDyn CEO says FDA has offered 'a good path forward' for its HIV drug https://ca.proactiveinvestors.com/companies/news/312107/cytodyn-ceo-says-fda-has-offered--a-good-path-forward--for-its-hiv-drug-12107.html Tue, 05 Feb 2019 17:30:00 -0500 https://ca.proactiveinvestors.com/companies/news/312107/cytodyn-ceo-says-fda-has-offered--a-good-path-forward--for-its-hiv-drug-12107.html CytoDyn wins key concession from FDA for flagship HIV drug leronlimab trial https://ca.proactiveinvestors.com/companies/news/213816/cytodyn-wins-key-concession-from-fda-for-flagship-hiv-drug-leronlimab-trial-213816.html Fri, 01 Feb 2019 13:18:00 -0500 https://ca.proactiveinvestors.com/companies/news/213816/cytodyn-wins-key-concession-from-fda-for-flagship-hiv-drug-leronlimab-trial-213816.html CytoDyn says it’s on the cusp of a breakthrough HIV treatment after Phase 3 trial https://ca.proactiveinvestors.com/companies/news/213647/cytodyn-says-its-on-the-cusp-of-a-breakthrough-hiv-treatment-after-phase-3-trial-213647.html Wed, 30 Jan 2019 20:20:00 -0500 https://ca.proactiveinvestors.com/companies/news/213647/cytodyn-says-its-on-the-cusp-of-a-breakthrough-hiv-treatment-after-phase-3-trial-213647.html CytoDyn aims to be 'paradigm-shifting' in cancer management with its platform drug leronlimab https://ca.proactiveinvestors.com/companies/news/311806/cytodyn-aims-to-be--paradigm-shifting--in-cancer-management-with-its-platform-drug-leronlimab-11806.html Fri, 11 Jan 2019 15:51:00 -0500 https://ca.proactiveinvestors.com/companies/news/311806/cytodyn-aims-to-be--paradigm-shifting--in-cancer-management-with-its-platform-drug-leronlimab-11806.html CytoDyn's injectable treatment does well in Aids trial https://ca.proactiveinvestors.com/companies/news/124921/cytodyn-s-injectable-treatment-does-well-in-aids-trial-124921.html Mon, 18 Apr 2016 13:28:00 -0400 https://ca.proactiveinvestors.com/companies/news/124921/cytodyn-s-injectable-treatment-does-well-in-aids-trial-124921.html